[{"title01":"Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients","title02":"Point-of-care <i>BCR::ABL1<\/i> transcript monitoring using capillary dried blood in chronic myeloid leukemia patients","journal":"Leukemia","issue":"2024 Jun 15. doi: 10.1038\/s41375-024-02285-9. Online ahead of print.","author":"Sala-Torra O, Beppu L, Wu Q, Welch E, Berthier E, Radich JP, Oehler VG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38879611"},{"title01":"Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations","title02":"Combination of menin and kinase inhibitors as an effective treatment for leukemia with <i>NUP98<\/i> translocations","journal":"Leukemia","issue":"2024 Jun 18. doi: 10.1038\/s41375-024-02312-9. Online ahead of print.","author":"Miao H, Chen D, Ropa J, Purohit T, Kim E, Sulis ML, Ferrando A, Cierpicki T, Grembecka J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38890447"},{"title01":"FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): The Mayo Clinic experience","title02":"FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(<i>DEK::NUP214<\/i>): The Mayo Clinic experience","journal":"Haematologica","issue":"2024 Jun 20. doi: 10.3324\/haematol.2024.285342. Online ahead of print.","author":"Csizmar CM, Saliba AN, Greipp PT, Alkhateeb H, Begna KH, Foran JM, Gangat N, Hogan WJ, Hook CC, Litzow MR, Mangaonkar AA, Palmer JM, Pardanani A, Shah MV, Tefferi A, Torghabeh MH, Wolanskyj-Spinner AP, Patnaik MM, Kaufmann SH, Al-Kali A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38899336"},{"title01":"ASXL1\/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia","title02":"<i>ASXL1\/TET2<\/i> genotype-based risk stratification outperforms <i>ASXL1<\/i> mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia","journal":"Haematologica","issue":"2024 Jun 20. doi: 10.3324\/haematol.2024.285410. Online ahead of print.","author":"Csizmar CM, Gurney M, Kanagal-Shamanna R, Chien K, Hammond D, Lasho TL, Finke CM, Dean C, Natu A, Mangaonkar AA, Al-Kali A, Gangat N, Tefferi A, Alkhateeb H, Garcia-Manero G, Komrokji RS, Ali NA, Padron E, Montalban-Bravo G, Patnaik MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38899337"},{"title01":"A novel TCF3::PIK3R1 fusion linked to decreased PI3K-AKT signalling activity in paediatric B-acute lymphoblastic leukaemia","title02":"A novel <i>TCF3::PIK3R1<\/i> fusion linked to decreased PI3K-AKT signalling activity in paediatric B-acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"2024 Jun 14. doi: 10.1111\/bjh.19587. Online ahead of print.","author":"Grady E, Biswas S, Dias T, McCarthy P, Tudose C, Betts D, Malone A, Bond J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38877747"},{"title01":"Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI-503 against MLL::AF9-driven acute myeloid leukaemia","title02":"Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI-503 against <i>MLL::AF9<\/i>-driven acute myeloid leukaemia","journal":"Br J Haematol","issue":"2024 Jun 15. doi: 10.1111\/bjh.19591. Online ahead of print.","author":"Zhu W, Ding Y, Huang W, Guo N, Ren Q, Wang N, Ma X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38877874"},{"title01":"Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma","title02":"Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <i>de novo<\/i> large B-cell lymphoma and transformed low-grade B-cell lymphoma","journal":"Haematologica","issue":"2024 Jun 20. doi: 10.3324\/haematol.2023.284664. Online ahead of print.","author":"Benjamini O, Fried S, Shouval R, Flynn JR, Beyar-Katz O, Leslie LA, Zucherman T, Yerushalmi R, Shem-Tov N, Palomba ML, Danylesko I, Sdayoor I, Malka H, Itzhaki O, Suh H, Devlin SM, Marcus R, Dahi PB, Jacoby E, Shah GL, Sauter CS, Ip A, Perales MA, Nagler A, Shimoni A, Scordo M, Avigdor A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38899351"},{"title01":"How risky is a second allogeneic stem cell transplantation?","title02":"How risky is a second allogeneic stem cell transplantation?","journal":"Leukemia","issue":"2024 Jun 25. doi: 10.1038\/s41375-024-02318-3. Online ahead of print.","author":"Penack O, Abouqateb M, Peczynski C, Boreland W, Kr\u00f6ger N, Zeiser R, Ciceri F, Schroeder T, Dreger P, Passweg J, Schetelig J, Stelljes M, Blau IW, Franke GN, Riesner K, Schoemans H, Moiseev I, Peric Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38918561"},{"title01":"Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs","title02":"Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs","journal":"Leukemia","issue":"2024 Jun 14. doi: 10.1038\/s41375-024-02284-w. Online ahead of print.","author":"Hoferkova E, Seda V, Kadakova S, Verner J, Loja T, Matulova K, Skuhrova Francova H, Ondrouskova E, Filip D, Blavet N, Boudny M, Mladonicka Pavlasova G, Vecera J, Ondrisova L, Pavelkova P, Hlavac K, Kostalova L, Michaelou A, Pospisilova S, Dorazilova J, Chochola V, Jaros J, Doubek M, Jarosova M, Hampl A, Vojtova L, Kren L, Mayer J, Mraz M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38877102"},{"title01":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","title02":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","journal":"Lancet Oncol","issue":"2024 Jun 14:S1470-2045(24)00282-1. doi: 10.1016\/S1470-2045(24)00282-1. Online ahead of print.","author":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Zweegman S, Caillon H, Caillot D, Avet-Loiseau H, Delforge M, Dejoie T, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Schiano de Colella JM, van de Donk NW, Wuill\u00e8me S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Hua W, Wang J, Tuozzo A, de Boer C, Rowe M, Vanquickelberghe V, Carson R, Vermeulen J, Corre J, Sonneveld P; Intergroupe Francophone du My\u00e9lome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38889735"},{"title01":"Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era","title02":"Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era","journal":"Haematologica","issue":"2024 Jun 20. doi: 10.3324\/haematol.2024.285256. Online ahead of print.","author":"Okada Y, Nakasone H, Kawamura S, Takano K, Yoshimura K, Tamaki M, Matsuoka A, Ishikawa T, Meno T, Nakamura Y, Kawamura M, Takeshita J, Yoshino N, Misaki Y, Kusuda M, Tanihara A, Kimura SI, Kako S, Kanda Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38899343"},{"title01":"Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action","title02":"Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action","journal":"Haematologica","issue":"2024 Jun 20. doi: 10.3324\/haematol.2024.285392. Online ahead of print.","author":"Gillis N, Ebied A, Thompson ZJ, Pidala JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38899345"},{"title01":"The impact of matched and mismatched donor-recipient genotypes for MDR1 polymorphisms (G2677TA, C1236T and C3435T) on the outcomes of patients after allogeneic haematopoietic stem cell transplantation","title02":"The impact of matched and mismatched donor-recipient genotypes for MDR1 polymorphisms (G2677TA, C1236T and C3435T) on the outcomes of patients after allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2024 Jun 26. doi: 10.1111\/bjh.19588. Online ahead of print.","author":"Duan Z, Zhang X, Liu Y, Wang J, Zhu H, Chen R, Xu W, Miao K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38924031"},{"title01":"Recent infection with SARS-CoV-2 in donors was associated with a higher incidence of acute graft-versus-host disease in recipients undergoing allogeneic haematopoietic stem cell transplantation","title02":"Recent infection with SARS-CoV-2 in donors was associated with a higher incidence of acute graft-versus-host disease in recipients undergoing allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2024 Jun 24. doi: 10.1111\/bjh.19594. Online ahead of print.","author":"Lin F, Xu L, Han T, Xu Z, Liu J, He Y, Chen Y, Chen H, Han W, Chen Y, Fu H, Zhang Y, Mo X, Wang F, Wang J, Cheng Y, Yan C, Sun H, Wang Y, Zhang X, Huang X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38924065"},{"title01":"Haploidentical bone marrow transplant for SCD","title02":"Haploidentical bone marrow transplant for SCD","journal":"Blood","issue":"2024 Jun 20;143(25):2677.","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38900480"},{"title01":"GVHD targets organoid-forming bile duct stem cells via a TGF-\u03b2-dependent manner","title02":"GVHD targets organoid-forming bile duct stem cells via a TGF-\u03b2-dependent manner","journal":"Blood","issue":"2024 Jun 21:blood.2023023060. doi: 10.1182\/blood.2023023060. Online ahead of print.","author":"Hasegawa Y, Hashimoto D, Zhang Z, Miyajima T, Saito Y, Li W, Kikuchi R, Senjo H, Sekiguchi T, Tateno T, Chen X, Yokoyama E, Takahashi S, Ohigashi H, Ara T, Hayase E, Yokota I, Teshima T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38905638"},{"title01":"Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance","title02":"Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance","journal":"Leukemia","issue":"2024 Jun 18. doi: 10.1038\/s41375-024-02300-z. Online ahead of print.","author":"McCarthy N, Gui G, Dumezy F, Roumier C, Andrew G, Green S, Jenkins M, Adams A, Khan N, Craddock C, Hourigan CS, Plesa A, Freeman S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38890448"},{"title01":"Histamine dihydrochloride and low-dose interleukin-2 has antileukemic efficacy in NPM1-mutated and myelomonocytic\/monocytic acute myeloid leukemia","title02":"Histamine dihydrochloride and low-dose interleukin-2 has antileukemic efficacy in NPM1-mutated and myelomonocytic\/monocytic acute myeloid leukemia","journal":"Haematologica","issue":"2024 Jun 20. doi: 10.3324\/haematol.2024.285342. Online ahead of print.","author":"Nilsson MS, Fiegl M, Hiddemann W, Sperr WR, Thor\u00e9n FB, Martner A, Hellstrand K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38899344"},{"title01":"CD19-CAR T-cell therapy with sorafenib in post-HSCT relapse of mixed phenotype acute leukaemia (MPAL) with phenotypic myeloid to lymphoid lineage switch-A case report and review of the literature","title02":"CD19-CAR T-cell therapy with sorafenib in post-HSCT relapse of mixed phenotype acute leukaemia (MPAL) with phenotypic myeloid to lymphoid lineage switch-A case report and review of the literature","journal":"Br J Haematol","issue":"2024 Jun 26. doi: 10.1111\/bjh.19608. Online ahead of print.","author":"Oszer A, Ko\u0142odrubiec J, Pawlik B, Marschollek P, \u0106wilichowska N, Jakubowska J, Bukowska-Strakova K, Surman M, Treli\u0144ska J, Miarka-Walczyk K, Haze N, Liszka K, Mielcarek-Siedziuk M, Ka\u0142wak K, Por\u0119ba M, Pastorczak A, Janczar S, M\u0142ynarski W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38924036"},{"title01":"Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study","title02":"Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study","journal":"Br J Haematol","issue":"2024 Jun 25. doi: 10.1111\/bjh.19610. Online ahead of print.","author":"Anastasopoulou S, Swann G, Andres-Jensen L, Attarbaschi A, Barzilai-Birenboim S, Erdelyi DJ, Escherich G, Hamadeh L, Harila A, Lopez-Lopez E, McGowan S, M\u00f6ricke A, Putti C, Sagi JC, Schmiegelow K, Ullrich NJ, van der Sluis IM, Wahid QU, Winick N, Sramkova L, Zalcberg Y, Zapotocka E, Bhojwani D, Halsey C; Ponte Di\u00a0Legno Neurotoxicity Working Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38924051"},{"title01":"Time for a new prognostic score in CLL?","title02":"Time for a new prognostic score in CLL?","journal":"Blood","issue":"2024 Jun 20;143(25):2561-2562.","author":"Forconi F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38900481"},{"title01":"How I Treat Infant Acute Lymphoblastic Leukemia","title02":"How I Treat Infant Acute Lymphoblastic Leukemia","journal":"Blood","issue":"2024 Jun 21:blood.2023023154. doi: 10.1182\/blood.2023023154. Online ahead of print.","author":"Bartram J, Ancliff P, Vora A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38905593"},{"title01":"Preclinical efficacy of potent and selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias","title02":"Preclinical efficacy of potent and selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias","journal":"Blood","issue":"2024 Jun 21:blood.2023022480. doi: 10.1182\/blood.2023022480. Online ahead of print.","author":"Kwon MC, Thuring JW, Querolle O, Dai X, Verhulst T, Pande V, Marien A, Goffin D, Wenge DV, Yue H, Cutler JA, Jin C, Perner F, Hogeling SM, Shaffer PL, Jacobs F, Vinken P, Cai W, Keersmaekers V, Eyassu F, Bhogal B, Verstraeten K, Ashkar SE, Perry JA, Jayaguru P, Barreyro L, Kuchnio A, Darville N, Krosky D, Urbanietz G, Verbist B, Edwards JP, Cowley GS, Kirkpatrick R, Steele R, Ferrante L, Guttke C, Daskalakis N, Pietsch EC, Wilson DM, Attar RM, Elsayed YA, Fischer ES, Schuringa JJ, Armstrong SA, Packman K, Philippar U.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38905635"},{"title01":"Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1-positive acute lymphoblastic leukemia","title02":"Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1-positive acute lymphoblastic leukemia","journal":"Blood","issue":"2024 Jun 25:blood.2024024838. doi: 10.1182\/blood.2024024838. Online ahead of print.","author":"Walczak P, Fodil S, Vignal N, Cabannes-Hamy A, Boissel N, Raffoux E, Cayuela JM, Goldwirt L, Lenglin\u00e9 E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38917352"},{"title01":"Early-life infection depletes preleukemic cells in a mouse model of hyperdiploid B-cell acute lymphoblastic leukemia","title02":"Early-life infection depletes preleukemic cells in a mouse model of hyperdiploid B-cell acute lymphoblastic leukemia","journal":"Blood","issue":"2024 Jun 14:blood.2024025038. doi: 10.1182\/blood.2024025038. Online ahead of print.","author":"Farrokhi A, Atre T, Salitra S, Aletaha M, M\u00e1rquez AC, Gynn M, Fidanza M, Jo S, Rolf N, Simmons K, Duque-Afonso J, Cleary ML, Seif AE, Kollmann TR, Gantt S, Reid GSD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38875504"},{"title01":"Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma","title02":"Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma","journal":"N Engl J Med","issue":"2024 Jun 20;390(23):2143-2155.","author":"Melani C, Lakhotia R, Pittaluga S, Phelan JD, Huang DW, Wright G, Simard J, Muppidi J, Thomas CJ, Ceribelli M, Tosto FA, Yang Y, Xu W, Davies-Hill T, Pack SD, Peer CJ, Arisa O, Mena E, Lindenberg L, Bergvall E, Portell CA, Farah RJ, Lee ST, Pradhan A, Morrison C, Tadese A, Juanitez AM, Lu C, Jacob A, Simmons H, Figg WD, Steinberg SM, Jaffe ES, Roschewski M, Staudt LM, Wilson WH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38899693"},{"title01":"ViPOR&#8217;s Venom &#8211; Rationally Targeting DLBCL with Precision","title02":"ViPOR&#8217;s Venom &#8211; Rationally Targeting DLBCL with Precision","journal":"N Engl J Med","issue":"2024 Jun 20;390(23):2209-2211.","author":"Goldstein JS, Alizadeh AA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38899699"},{"title01":"First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma","title02":"First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma","journal":"Leukemia","issue":"2024 Jun 21. doi: 10.1038\/s41375-024-02302-x. Online ahead of print.","author":"Gibouin VC, Durand M, Boudesco C, Hermetet F, Nozickova K, Chassagne-Clement C, Abdelwahed M, Klener P, Garrido C, Jego G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38906964"},{"title01":"P4HA2 hydroxylates SUFU to regulate the paracrine Hedgehog signaling and promote B-cell lymphoma progression","title02":"P4HA2 hydroxylates SUFU to regulate the paracrine Hedgehog signaling and promote B-cell lymphoma progression","journal":"Leukemia","issue":"2024 Jun 22. doi: 10.1038\/s41375-024-02313-8. Online ahead of print.","author":"Li Q, Liu Y, Wu J, Zhu Z, Fan J, Zhai L, Wang Z, Du G, Zhang L, Hu J, Ma DK, Liu JO, Huang H, Tan M, Dang Y, Jiang W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38909089"},{"title01":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","title02":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","journal":"Lancet Haematol","issue":"2024 Jun 13:S2352-3026(24)00166-2. doi: 10.1016\/S2352-3026(24)00166-2. Online ahead of print.","author":"Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, Christensen JH, Hess B, Tilly H, Cordoba R, Lewis DJ, Okada C, Hutchings M, Clausen MR, Sancho JM, Cochrane T, Lepp\u00e4 S, Chamuleau MED, Gernhardt D, Alt\u0131nta\u015f I, Liu Y, Ahmadi T, Dinh MH, Hoehn D, Favaro E, Elliott B, Thieblemont C, Vose JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38889737"},{"title01":"Machine Learning for Automated Interpretation of Fluorodeoxyglucose-Positron Emission Tomography Scans in Lymphoma","title02":"Machine Learning for Automated Interpretation of Fluorodeoxyglucose-Positron Emission Tomography Scans in Lymphoma","journal":"J Clin Oncol","issue":"2024 Jun 21:JCO2400675. doi: 10.1200\/JCO.24.00675. Online ahead of print.","author":"Sch\u00f6der H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38905572"},{"title01":"HHV-6 lymphadenitis with DRESS syndrome: another lymphoma mimic","title02":"HHV-6 lymphadenitis with DRESS syndrome: another lymphoma mimic","journal":"Blood","issue":"2024 Jun 20;143(25):2671.","author":"Flaifel A, Rocco JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38900479"},{"title01":"CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma","title02":"CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma","journal":"Leukemia","issue":"2024 Jun 20. doi: 10.1038\/s41375-024-02303-w. Online ahead of print.","author":"Ismael A, Robinette AJ, Huric L, Schuetz J, Dona K, Benson D, Cocucci E, Cottini F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38902472"},{"title01":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","title02":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","journal":"Lancet Oncol","issue":"2024 Jun 14:S1470-2045(24)00282-1. doi: 10.1016\/S1470-2045(24)00282-1. Online ahead of print.","author":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Zweegman S, Caillon H, Caillot D, Avet-Loiseau H, Delforge M, Dejoie T, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Schiano de Colella JM, van de Donk NW, Wuill\u00e8me S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Hua W, Wang J, Tuozzo A, de Boer C, Rowe M, Vanquickelberghe V, Carson R, Vermeulen J, Corre J, Sonneveld P; Intergroupe Francophone du My\u00e9lome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38889735"},{"title01":"Daratumumab maintenance in patients with myeloma","title02":"Daratumumab maintenance in patients with myeloma","journal":"Lancet Oncol","issue":"2024 Jun 14:S1470-2045(24)00341-3. doi: 10.1016\/S1470-2045(24)00341-3. Online ahead of print.","author":"Beksac M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38889736"},{"title01":"Receptor T-Cell Chimeric Antigen Approach Used for the Prediction Model Treatment for Relapsed\/Refractory Multiple Myeloma","title02":"Receptor T-Cell Chimeric Antigen Approach Used for the Prediction Model Treatment for Relapsed\/Refractory Multiple Myeloma","journal":"J Clin Oncol","issue":"2024 Jun 24:JCO2400544. doi: 10.1200\/JCO.24.00544. Online ahead of print.","author":"Yin Z, Zhang Q, Ou R, Liu S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38913961"},{"title01":"Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma","title02":"Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma","journal":"J Clin Oncol","issue":"2024 Jun 16:JCO2401008. doi: 10.1200\/JCO.24.01008. Online ahead of print.","author":"Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, Zonder JA, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min CK, Vekemans MC, Munder M, Byun JM, Mart\u00ednez-Lopez J, Cassady K, DeVeaux M, Chokshi D, Boyapati A, Hazra A, Yancopoulos GD, Sirulnik LA, Rodriguez Lorenc K, Kroog GS, Houvras Y, Dhodapkar MV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38879802"},{"title01":"Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells","title02":"Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells","journal":"Br J Haematol","issue":"2024 Jun 18. doi: 10.1111\/bjh.19589. Online ahead of print.","author":"Ortiz de Landazuri I, Oliver-Cald\u00e9s A, Espa\u00f1ol-Rego M, Agull\u00f3 C, Contreras MT, Zabaleta A, Puig N, Caba\u00f1as V, Gonz\u00e1lez-Calle V, Zugasti I, Inog\u00e9s S, Rodr\u00edguez Otero P, Martin-Antonio B, Reguera JL, L\u00f3pez-Diaz de Cerio A, Ar\u00f3stegui JI, Uribe-Herranz M, Ben\u00edtez-Ribas D, Rodr\u00edguez-Lobato LG, Gonz\u00e1lez EA, Tovar N, Charry P, Navarro S, Rosi\u00f1ol L, Tr\u00e9boles K, Mora G, Yag\u00fce J, Moraleda JM, Urbano-Ispizua \u00c1, Mateos MV, Pascal M, Paiva B, Juan M, Fern\u00e1ndez de Larrea C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38894496"},{"title01":"Immunogenic therapy: new actors in myeloma","title02":"Immunogenic therapy: new actors in myeloma","journal":"Blood","issue":"2024 Jun 20;143(25):2564-2565.","author":"Solimando AG, Vacca A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38900472"},{"title01":"Snapper-Schneid bodies (coarse cytoplasmic granules) in a patient with multiply relapsed multiple myeloma","title02":"Snapper-Schneid bodies (coarse cytoplasmic granules) in a patient with multiply relapsed multiple myeloma","journal":"Blood","issue":"2024 Jun 13;143(24):2559.","author":"Nichols MM, Pozdnyakova O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38869920"},{"title01":"NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in Multiple Myeloma","title02":"NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in Multiple Myeloma","journal":"Blood","issue":"2024 Jun 14:blood.2023023529. doi: 10.1182\/blood.2023023529. Online ahead of print.","author":"Blanquart E, Ekren R, Rigaud B, Joubert MV, Baylot V, Daunes H, Cuisinier M, Villard M, Carri\u00e9 N, Mazzotti C, Lucca LE, Perrot A, Corre J, Walzer T, Avet-Loiseau H, Axisa PP, Martinet L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38875515"},{"title01":"Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells","title02":"Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells","journal":"Leukemia","issue":"2024 Jun 21. doi: 10.1038\/s41375-024-02320-9. Online ahead of print.","author":"Chatain N, Baumeister J, Szymanski de Toledo MA, Wong DWL, Gupta S, Pannen K, Junge B, Br\u00fcmmendorf TH, Boor P, Koschmieder S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38906962"},{"title01":"Bone marrow transplantation reduces FGF-23 levels and restores bone formation in myelodysplastic neoplasms","title02":"Bone marrow transplantation reduces FGF-23 levels and restores bone formation in myelodysplastic neoplasms","journal":"Leukemia","issue":"2024 Jun 21. doi: 10.1038\/s41375-024-02315-6. Online ahead of print.","author":"Weidner H, Baschant U, Ledesma-Colunga MG, Basiak K, Tsourdi E, Sockel K, G\u00f6tze KS, Rivi\u00e8re J, Platzbecker U, Hofbauer LC, Rauner M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38906963"},{"title01":"Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells","title02":"Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells","journal":"Leukemia","issue":"2024 Jun 21. doi: 10.1038\/s41375-024-02320-9. Online ahead of print.","author":"Chatain N, Baumeister J, Szymanski de Toledo MA, Wong DWL, Gupta S, Pannen K, Junge B, Br\u00fcmmendorf TH, Boor P, Koschmieder S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38906962"},{"title01":"How risky is a second allogeneic stem cell transplantation?","title02":"How risky is a second allogeneic stem cell transplantation?","journal":"Leukemia","issue":"024 Jun 25. doi: 10.1038\/s41375-024-02318-3. Online ahead of print.","author":"Penack O, Abouqateb M, Peczynski C, Boreland W, Kr\u00f6ger N, Zeiser R, Ciceri F, Schroeder T, Dreger P, Passweg J, Schetelig J, Stelljes M, Blau IW, Franke GN, Riesner K, Schoemans H, Moiseev I, Peric Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38918561"},{"title01":"Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action","title02":"Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action","journal":"Haematologica","issue":"2024 Jun 20. doi: 10.3324\/haematol.2024.285392. Online ahead of print.","author":"Gillis N, Ebied A, Thompson ZJ, Pidala JA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38899345"},{"title01":"The impact of matched and mismatched donor-recipient genotypes for MDR1 polymorphisms (G2677TA, C1236T and C3435T) on the outcomes of patients after allogeneic haematopoietic stem cell transplantation","title02":"The impact of matched and mismatched donor-recipient genotypes for MDR1 polymorphisms (G2677TA, C1236T and C3435T) on the outcomes of patients after allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2024 Jun 26. doi: 10.1111\/bjh.19588. Online ahead of print.","author":"Duan Z, Zhang X, Liu Y, Wang J, Zhu H, Chen R, Xu W, Miao K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38924031"},{"title01":"CD19-CAR T-cell therapy with sorafenib in post-HSCT relapse of mixed phenotype acute leukaemia (MPAL) with phenotypic myeloid to lymphoid lineage switch-A case report and review of the literature","title02":"CD19-CAR T-cell therapy with sorafenib in post-HSCT relapse of mixed phenotype acute leukaemia (MPAL) with phenotypic myeloid to lymphoid lineage switch-A case report and review of the literature","journal":"Br J Haematol","issue":"2024 Jun 26. doi: 10.1111\/bjh.19608. Online ahead of print.","author":"Oszer A, Ko\u0142odrubiec J, Pawlik B, Marschollek P, \u0106wilichowska N, Jakubowska J, Bukowska-Strakova K, Surman M, Treli\u0144ska J, Miarka-Walczyk K, Haze N, Liszka K, Mielcarek-Siedziuk M, Ka\u0142wak K, Por\u0119ba M, Pastorczak A, Janczar S, M\u0142ynarski W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38924036"},{"title01":"Recent infection with SARS-CoV-2 in donors was associated with a higher incidence of acute graft-versus-host disease in recipients undergoing allogeneic haematopoietic stem cell transplantation","title02":"Recent infection with SARS-CoV-2 in donors was associated with a higher incidence of acute graft-versus-host disease in recipients undergoing allogeneic haematopoietic stem cell transplantation","journal":"Br J Haematol","issue":"2024 Jun 24. doi: 10.1111\/bjh.19594. Online ahead of print.","author":"Lin F, Xu L, Han T, Xu Z, Liu J, He Y, Chen Y, Chen H, Han W, Chen Y, Fu H, Zhang Y, Mo X, Wang F, Wang J, Cheng Y, Yan C, Sun H, Wang Y, Zhang X, Huang X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38924065"},{"title01":"GVHD targets organoid-forming bile duct stem cells via a TGF-\u03b2-dependent manner","title02":"GVHD targets organoid-forming bile duct stem cells via a TGF-\u03b2-dependent manner","journal":"Blood","issue":"2024 Jun 21:blood.2023023060. doi: 10.1182\/blood.2023023060. Online ahead of print.","author":"Hasegawa Y, Hashimoto D, Zhang Z, Miyajima T, Saito Y, Li W, Kikuchi R, Senjo H, Sekiguchi T, Tateno T, Chen X, Yokoyama E, Takahashi S, Ohigashi H, Ara T, Hayase E, Yokota I, Teshima T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38905638"},{"title01":"DNMT3A gates IFN-induced MPN HSC exhaustion","title02":"DNMT3A gates IFN-induced MPN HSC exhaustion","journal":"Blood","issue":"2024 Jun 13;143(24):2445-2446.","author":"Constantinescu SN, Vainchenker W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38869916"},{"title01":"Leveraging deep learning for detecting red blood cell morphological changes in blood films from children with severe malaria anaemia","title02":"Leveraging deep learning for detecting red blood cell morphological changes in blood films from children with severe malaria anaemia","journal":"Br J Haematol","issue":"2024 Jun 18. doi: 10.1111\/bjh.19599. Online ahead of print.","author":"Moysis E, Brown BJ, Shokunbi W, Manescu P, Fernandez-Reyes D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38894606"},{"title01":"Emerging genetic technologies informing personalized medicine in SDS and other inherited bone marrow failure disorders","title02":"Emerging genetic technologies informing personalized medicine in SDS and other inherited bone marrow failure disorders","journal":"Blood","issue":"2024 Jun 21:blood.2023019986. doi: 10.1182\/blood.2023019986. Online ahead of print.","author":"Cull AH, Kent DG, Warren AJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38905596"},{"title01":"A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia","title02":"A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia","journal":"N Engl J Med","issue":"2024 Jun 20;390(23):2178-2190.","author":"Chen Y, Xu Y, Li H, Sun T, Cao X, Wang Y, Xue F, Liu W, Liu X, Dong H, Fu R, Dai X, Wang W, Ma Y, Song Z, Chi Y, Ju M, Gu W, Pei X, Yang R, Zhang L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38899695"},{"title01":"Sovleplenib in immune thrombocytopenia","title02":"Sovleplenib in immune thrombocytopenia","journal":"Lancet Haematol","issue":"2024 Jun 13:S2352-3026(24)00180-7. doi: 10.1016\/S2352-3026(24)00180-7. Online ahead of print.","author":"Mingot-Castellano ME.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38885671"},{"title01":"Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study","title02":"Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study","journal":"Lancet Haematol","issue":"2024 Jun 13:S2352-3026(24)00139-X. doi: 10.1016\/S2352-3026(24)00139-X. Online ahead of print.","author":"Hu Y, Liu X, Zhou H, Wang S, Huang R, Wang Y, Du X, Sun J, Zhou Z, Yan Z, Chen W, Wang W, Liu Q, Zeng Q, Gong Y, Yin J, Shen X, Ye B, Chen Y, Xu Y, Sun H, Cheng Y, Liu Z, Wang C, Yuan G, Zhang X, Li X, Cheng P, Guo X, Jiang Z, Yang F, Yang L, Luo C, Xiao T, Fu S, Yin H, Guo X, Xu Q, Fan S, Shi MM, Su W, Mei H, Yang R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38885672"},{"title01":"Avatrombopag plus fostamatinib combination as treatment in patients with multirefractory immune thrombocytopenia","title02":"Avatrombopag plus fostamatinib combination as treatment in patients with multirefractory immune thrombocytopenia","journal":"Br J Haematol","issue":"2024 Jun 19. doi: 10.1111\/bjh.19602. Online ahead of print.","author":"Mingot-Castellano ME, Bastida JM, Ghanima W, Ruiz Sainz E, Nu\u00f1ez Vazquez R, Pedrote Amador B, Abdel-Kader Mart\u00edn L, Piquer-Monsonis D, Canaro M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38895923"},{"title01":"Response and Resistance to Menin Inhibitor in UBTF-Tandem Duplication AML","title02":"Response and Resistance to Menin Inhibitor in UBTF-Tandem Duplication AML","journal":"N Engl J Med","issue":"2024 Jun 27;390(24):2323-2325.","author":"Tiong IS, Ritchie DS, Blombery P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38924737"},{"title01":"Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions","title02":"Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions","journal":"Leukemia","issue":"2024 Jun 20. doi: 10.1038\/s41375-024-02319-2. Online ahead of print.","author":"Abou Dalle I, Moukalled N, El Cheikh J, Mohty M, Bazarbachi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38902471"},{"title01":"Pivotal role of the endoplasmic reticulum stress-related XBP1s\/miR-22\/SIRT1 axis in acute myeloid leukemia apoptosis and response to chemotherapy","title02":"Pivotal role of the endoplasmic reticulum stress-related XBP1s\/miR-22\/SIRT1 axis in acute myeloid leukemia apoptosis and response to chemotherapy","journal":"Leukemia","issue":"2024 Jun 22. doi: 10.1038\/s41375-024-02321-8. Online ahead of print.","author":"Philippe C, Jaud M, F\u00e9ral K, Gay A, Van Den Berghe L, Farce M, Bousquet M, Pyronnet S, Mazzolini L, Rouault-Pierre K, Touriol C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38909090"},{"title01":"Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia","title02":"Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia","journal":"Leukemia","issue":"2024 Jun 24. doi: 10.1038\/s41375-024-02296-6. Online ahead of print.","author":"Yanagiya R, Miyatake Y, Watanabe N, Shimizu T, Kanamori A, Ueno M, Okabe S, Carreras J, Nakayama S, Hasegawa A, Kameda K, Kamakura T, Nakagawa S, Yamauchi T, Maeda T, Ishii K, Matsuura T, Handa H, Hirao A, Ishizawa K, Onizuka M, Mashima T, Nakamura N, Ando K, Kotani A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38914715"},{"title01":"Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia","title02":"Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia","journal":"Leukemia","issue":"2024 Jun 24. doi: 10.1038\/s41375-024-02301-y. Online ahead of print.","author":"Pozzo F, Forestieri G, Vit F, Ianna G, Tissino E, Bittolo T, Papotti R, Gaglio A, Terzi di Bergamo L, Steffan A, Polesel J, Bulian P, Laureana R, Tafuri A, Chiarenza A, Di Raimondo F, Olivieri J, Zaja F, Laurenti L, Del Principe MI, Postorino M, Del Poeta G, Bomben R, Zucchetto A, Rossi D, Gattei V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38914716"},{"title01":"Is there really an accelerated phase of chronic myeloid leukaemia?","title02":"Is there really an accelerated phase of chronic myeloid leukaemia?","journal":"Leukemia","issue":"2024 Jun 25. doi: 10.1038\/s41375-024-02316-5. Online ahead of print.","author":"Gale RP, Jiang Q, Apperley JF, Hochhaus A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38918562"},{"title01":"Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs","title02":"Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs","journal":"Leukemia","issue":"2024 Jun 14. doi: 10.1038\/s41375-024-02284-w. Online ahead of print.","author":"Hoferkova E, Seda V, Kadakova S, Verner J, Loja T, Matulova K, Skuhrova Francova H, Ondrouskova E, Filip D, Blavet N, Boudny M, Mladonicka Pavlasova G, Vecera J, Ondrisova L, Pavelkova P, Hlavac K, Kostalova L, Michaelou A, Pospisilova S, Dorazilova J, Chochola V, Jaros J, Doubek M, Jarosova M, Hampl A, Vojtova L, Kren L, Mayer J, Mraz M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38877102"},{"title01":"Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry","title02":"Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry","journal":"Haematologica","issue":"2024 Jun 20. doi: 10.3324\/haematol.2023.284786. Online ahead of print.","author":"Herbaux C, Bret C, Bachy E, Bories P, Di Blasi R, Cuffel A, Gastinne T, Lamy T, Roussel M, Bouabdallah K, Beauvais D, Cartron G, Bay JO, Blaise D, Rubio MT, Mohty M, Le Bras F, Casasnovas O, Guy J, Guidez S, Llorente CC, Hermine O, La Rochelle LD, Carras S, Guffroy B, Caillat-Zucman S, Houot R, Le Gouill S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38899352"},{"title01":"Large B-cell lymphoma with mystery rearrangement: Applying Hi-C to the detection of clinically relevant structural abnormalities","title02":"Large B-cell lymphoma with mystery rearrangement: Applying Hi-C to the detection of clinically relevant structural abnormalities","journal":"Br J Haematol","issue":"2024 Jun 25. doi: 10.1111\/bjh.19611. Online ahead of print.","author":"Prior D, Schmitt AD, Louissaint A, Mata DA, Massaro S, Nardi V, Xu ML.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38924537"},{"title01":"Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study","title02":"Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study","journal":"Br J Haematol","issue":"2024 Jun 15. doi: 10.1111\/bjh.19590. Online ahead of print.","author":"Barone A, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, Di Rocco A, Tisi MC, Barbui AM, Farina M, Brunello L, Di Chio MC, Novo M, Musso M, Olivieri J, Trotta GE, Dodero A, Aiello A, Corradini P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38877876"},{"title01":"ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?","title02":"<i>ETV6::RUNX1<\/i> Acute Lymphoblastic Leukemia: how much therapy is needed for cure?","journal":"Leukemia","issue":"2024 Jun 6. doi: 10.1038\/s41375-024-02287-7. Online ahead of print.","author":"\u00d8stergaard A, Fiocco M, de Groot-Kruseman H, Moorman AV, Vora A, Zimmermann M, Schrappe M, Biondi A, Escherich G, Stary J, Imai C, Imamura T, Heyman M, Schmiegelow K, Pieters R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38844578"},{"title01":"An investigation of germline variants of HAVCR2 in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population","title02":"An investigation of germline variants of <i>HAVCR2<\/i> in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population","journal":"Haematologica","issue":"2024 Jun 13. doi: 10.3324\/haematol.2023.284738. Online ahead of print.","author":"Cheng J, Xi L, Jang Y, Kim J, Wang HW, Pittaluga S, Jaffe ES, Raffeld M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38867583"},{"title01":"Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma","title02":"Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma","journal":"Blood","issue":"2024 May 31:blood.2024023962. doi: 10.1182\/blood.2024023962. Online ahead of print.","author":"Smith MR, Jegede O, Martin P, Till B, Parekh S, Yang DT, Hsi ED, Witzig TE, Dave SS, Scott DW, Hanson CA, Kostakoglu L, Abdel Samad NN, Casulo C, Bartlett NL, Caimi PF, Al Baghdadi T, Blum K, Romer M, Inwards DJ, Lerner R, Wagner L, Little RF, Friedberg JW, Leonard JP, Kahl BS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38820500"},{"title01":"Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma","title02":"Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma","journal":"N Engl J Med","issue":"2024 Jun 1. doi: 10.1056\/NEJMoa2405090. Online ahead of print.","author":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balar\u00ed AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38828933"},{"title01":"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma","title02":"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma","journal":"N Engl J Med","issue":"2024 Jun 2. doi: 10.1056\/NEJMoa2403407. Online ahead of print.","author":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Morris K, Pompilus F, Phillips-Jones A, Zhou XL, Fulci G, Sule N, Kremer BE, Opalinska J, Mateos MV, Trudel S; DREAMM-8 Investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38828951"},{"title01":"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","title02":"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","journal":"N Engl J Med","issue":"2024 Jun 3. doi: 10.1056\/NEJMoa2400712. Online ahead of print.","author":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, H\u00e1jek R, Liu Z, Minarik J, Moreau P, Romejko-Jarosinska J, Spicka I, Vorobyev VI, Besemer B, Ishida T, Janowski W, Kalayoglu-Besisik S, Parmar G, Robak P, Zamagni E, Goldschmidt H, Martin TG, Manier S, Mohty M, Oprea C, Br\u00e9geault MF, Mac\u00e9 S, Berthou C, Bregman D, Klippel Z, Orlowski RZ; IMROZ Study Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38832972"},{"title01":"CD8(+) CD28(-) regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study","title02":"CD8(+) CD28(-) regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study","journal":"Leukemia","issue":"2024 Jun 3. doi: 10.1038\/s41375-024-02290-y. Online ahead of print.","author":"Kriegsmann K, Ton GNHQ, Awwad MHS, Benner A, Bertsch U, Besemer B, H\u00e4nel M, Fenk R, Munder M, D\u00fcrig J, Blau IW, Huhn S, Hose D, Jauch A, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A, Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens UM, Kunz C, Hensel M, Seidel-Gl\u00e4tzer A, Weisel KC, Salwender HJ, M\u00fcller-Tidow C, Raab MS, Goldschmidt H, Mai EK, Hundemer M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38830959"},{"title01":"Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee","title02":"Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee","journal":"Lancet Oncol","issue":"2024 May 28:S1470-2045(24)00094-9. doi: 10.1016\/S1470-2045(24)00094-9. Online ahead of print.","author":"Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD Jr, Kumar S, Martin T; International Myeloma Working Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38821074"},{"title01":"Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells","title02":"Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells","journal":"Haematologica","issue":"2024 Jun 13. doi: 10.3324\/haematol.2024.285368. Online ahead of print.","author":"Kikuchi J, Hori M, Osada N, Matsuoka S, Suzuki A, Kakugawa S, Yasui H, Harada T, Tenshin H, Abe M, Nakasone H, Furukawa Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38867588"},{"title01":"Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study","title02":"Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study","journal":"Haematologica","issue":"2024 Jun 6. doi: 10.3324\/haematol.2024.285534. Online ahead of print.","author":"Lee JH, Choi J, Min CK, Park SS, Jo JC, Lee YJ, Kim JS, Eom HS, Jung J, Moon JH, Cho HJ, Lee MW, Yoon SS, Byun JM, Lee JH, Lee JJ, Jung SH, Shin HJ, Kim DY, Yi JH, Lee SS, Do YR, Yoon DH, Cho H, Lee WS, Lee HS, Uhm J, Kim HJ, Jang HR, Kim SH, Kim K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38841794"},{"title01":"Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21","title02":"Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21","journal":"Br J Haematol","issue":"2024 Jun 8. doi: 10.1111\/bjh.19578. Online ahead of print.","author":"Lim S, Reynolds J, Quach H, Hutchinson A, Kerridge I, Janowski W, Bergin K, Spencer A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38850184"},{"title01":"Blood, the hidden side of myeloma?","title02":"Blood, the hidden side of myeloma?","journal":"Blood","issue":"2024 Jun 6;143(23):2344-2345.","author":"Corre J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38842860"},{"title01":"PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire","title02":"PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire","journal":"Haematologica","issue":"2024 Jun 13. doi: 10.3324\/haematol.2024.284968. Online ahead of print.","author":"Kaphan E, Bettega F, Vallet N, Fegueux N, Robin M, Bazarbachi A, Nguyen S, Beauvais D, Forcade E, De Oca MCM, Devillier R, Chevallier P, Loschi M, Huynh A, Bay JO, Rubio MT, Suarez F, Francois S, Poire X, Contentin N, Desmier D, Charbonnier A, Cornillon J, Chantepie S, Turlure P, Bulabois CE, Michonneau D, Villate A; SFGM-TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38867585"},{"title01":"Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21","title02":"Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21","journal":"Br J Haematol","issue":"2024 Jun 8. doi: 10.1111\/bjh.19578. Online ahead of print.","author":"Lim S, Reynolds J, Quach H, Hutchinson A, Kerridge I, Janowski W, Bergin K, Spencer A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38850184"},{"title01":"Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation-A\u00a0secondary CIBMTR analysis","title02":"Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation-A\u00a0secondary CIBMTR analysis","journal":"Br J Haematol","issue":"2024 May 30. doi: 10.1111\/bjh.19506. Online ahead of print.","author":"Schoettler ML, Westbrook A, Watkins B, Stenger E, Qayed M, Chonat S, Williams KM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38817006"},{"title01":"Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia","title02":"Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia","journal":"Br J Haematol","issue":"2024 Jun 4. doi: 10.1111\/bjh.19552. Online ahead of print.","author":"Ronnacker J, Urbahn MA, Reicherts C, Kolloch L, Berning P, Sandmann S, E\u00dfeling E, Call S, Floeth M, Marx J, Albring J, Mikesch JH, Schliemann C, Lenz G, Stelljes M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38831752"},{"title01":"How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients","title02":"How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients","journal":"Blood","issue":"2024 Jun 12:blood.2023023249. doi: 10.1182\/blood.2023023249. Online ahead of print.","author":"Lai YK, Sharifi H, Hsu JL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38864640"},{"title01":"PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire","title02":"PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire","journal":"Haematologica","issue":"2024 Jun 13. doi: 10.3324\/haematol.2024.284968. Online ahead of print.","author":"Kaphan E, Bettega F, Vallet N, Fegueux N, Robin M, Bazarbachi A, Nguyen S, Beauvais D, Forcade E, De Oca MCM, Devillier R, Chevallier P, Loschi M, Huynh A, Bay JO, Rubio MT, Suarez F, Francois S, Poire X, Contentin N, Desmier D, Charbonnier A, Cornillon J, Chantepie S, Turlure P, Bulabois CE, Michonneau D, Villate A; SFGM-TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38867585"},{"title01":"Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation-A\u00a0secondary CIBMTR analysis","title02":"Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation-A\u00a0secondary CIBMTR analysis","journal":"Br J Haematol","issue":"2024 May 30. doi: 10.1111\/bjh.19506. Online ahead of print.","author":"Schoettler ML, Westbrook A, Watkins B, Stenger E, Qayed M, Chonat S, Williams KM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38817006"},{"title01":"Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia","title02":"Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia","journal":"Br J Haematol","issue":"2024 Jun 4. doi: 10.1111\/bjh.19552. Online ahead of print.","author":"Ronnacker J, Urbahn MA, Reicherts C, Kolloch L, Berning P, Sandmann S, E\u00dfeling E, Call S, Floeth M, Marx J, Albring J, Mikesch JH, Schliemann C, Lenz G, Stelljes M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38831752"},{"title01":"How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients","title02":"How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients","journal":"Blood","issue":"2024 Jun 12:blood.2023023249. doi: 10.1182\/blood.2023023249. Online ahead of print.","author":"Lai YK, Sharifi H, Hsu JL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38864640"},{"title01":"The early and rapid response to daratumumab in children with chronic refractory immune thrombocytopenia from a referral single centre of China","title02":"The early and rapid response to daratumumab in children with chronic refractory immune thrombocytopenia from a referral single centre of China","journal":"Br J Haematol","issue":"2024 Jun 3. doi: 10.1111\/bjh.19553. Online ahead of print.","author":"Hu Y, Wang Z, Ma J, Wang N, Meng J, Dong S, Chen Z, Cheng X, Wu R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38831655"},{"title01":"Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice","title02":"Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice","journal":"Blood","issue":"2024 Jun 6:blood.2024024250. doi: 10.1182\/blood.2024024250. Online ahead of print.","author":"Gonzalez-Lopez TJ, Bermejo N, Cardesa-Cabrera R, Mart\u00ednez V, Aguilar-Monserrate G, P\u00e9rez Segura G, Garc\u00eda AD, Luis-Navarro J, Lakhwani S, Acedo N, Lozano ML, Bernat S, Torres-Tienza A, Ruano A, Jarque I, Gal\u00e1n Alvarez P, Benet Campos C, Marcellini-Antonio S, Jimenez-B\u00e1rcenas R, Mart\u00ednez-Carballeira D, de Miguel Llorente D, Perona Bl\u00e1zquez \u00c1, Gonz\u00e1lez-Gasc\u00f3n-Y-Mar\u00edn I, Lopez-Ansoar E, Alonso Alonso JM, Bengochea-Casado ML, D\u00edaz G\u00e1lvez FJ, Moret\u00f3 A, Moreno G, Hern\u00e1ndez-Martin R, de Cabo E, Davila-Valls J, Cuesta A, Pastoriza Cruz C, Hermida G, Garc\u00eda C, Pozas-Ma\u00f1as MA, Aguilar-Franco C, Fernandez-Jimenez D, Navas-Elorza B, L\u00f3pez-Santamar\u00eda Castro C, Lorenzo Vizcaya A, Ort\u00edn X, Pintos MG, Piernas S, D\u00edaz-Santa J, Soto-Ortega I Dr, Provan D, Garc\u00eda-Donas Gabald\u00f3n G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38843478"},{"title01":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia","title02":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia","journal":"N Engl J Med","issue":"2024 May 31. doi: 10.1056\/NEJMoa2400858. Online ahead of print.","author":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38820078"},{"title01":"Hairy cell leukemia variant and WHO classification correspondence Re: 5(th) edition WHO classification haematolymphoid tumors: lymphoid neoplasms","title02":"Hairy cell leukemia variant and WHO classification correspondence Re: 5(th) edition WHO classification haematolymphoid tumors: lymphoid neoplasms","journal":"Leukemia","issue":"2024 Jun 8. doi: 10.1038\/s41375-024-02280-0. Online ahead of print.","author":"Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, Bhat SA, Blachly J, Broccoli A, Call T, Dearden C, Dietrich S, Else M, Epperla N, Fagarasanu A, Falini B, Forconi F, Gozzetti A, Hampel P, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kreitman RJ, Lauria F, Lozanski G, Oakes CC, Parikh SA, Park J, Quest G, Rai K, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, W\u00f6rmann B, Zent CS, Zenz T, Zinzani PL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38851853"},{"title01":"Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia","title02":"Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia","journal":"Leukemia","issue":"2024 Jun 1. doi: 10.1038\/s41375-024-02294-8. Online ahead of print.","author":"Shao Y, Kay NE, Gale RP, Liang Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38824147"},{"title01":"Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203","title02":"Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203","journal":"Leukemia","issue":"2024 Jun 3. doi: 10.1038\/s41375-024-02288-6. Online ahead of print.","author":"Zhang MY, Othus M, McMillen K, Erba HP, Garcia-Manero G, Pagel JM, Sorror ML, Percival MM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38830960"},{"title01":"GAIA\/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia","title02":"GAIA\/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia","journal":"Lancet Oncol","issue":"2024 Jun;25(6):685-687.","author":"Rogers KA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38821078"},{"title01":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","title02":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","journal":"Lancet Oncol","issue":"2024 Jun;25(6):744-759.","author":"F\u00fcrstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindstr\u00f6m V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, N\u00f6sslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, D\u00fcrig J, Stehle A, V\u00f6hringer M, B\u00f6ttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Br\u00fcggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38821083"},{"title01":"Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study","title02":"Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study","journal":"Lancet Haematol","issue":"2024 May 30:S2352-3026(24)00132-7. doi: 10.1016\/S2352-3026(24)00132-7. Online ahead of print.","author":"Salamero O, Molero A, P\u00e9rez-Sim\u00f3n JA, Arnan M, Coll R, Garcia-Avila S, Acu\u00f1a-Cruz E, Cano I, Somervaille TCP, Gutierrez S, Ar\u00e9valo MI, Xaus J, Buesa C, Lim\u00f3n A, Faller DV, Bosch F, Montesinos P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38824932"},{"title01":"Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials","title02":"Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials","journal":"J Clin Oncol","issue":"2024 Jun 6:JCO2302717. doi: 10.1200\/JCO.23.02717. Online ahead of print.","author":"Reed DR, Tulpule A, Metts J, Trucco M, Robertson-Tessi M, O'Donohue TJ, Iglesias-Cardenas F, Isakoff MS, Mauguen A, Shukla N, Dela Cruz FS, Tap W, Kentsis A, Morris CD, Hameed M, Honeyman JN, Behr GG, Sulis ML, Ortiz MV, Slotkin E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38843482"},{"title01":"Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children&#8217;s Oncology Group trial AALL15P1","title02":"Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children&#8217;s Oncology Group trial AALL15P1","journal":"Haematologica","issue":"2024 Jun 13. doi: 10.3324\/haematol.2024.285158. Online ahead of print.","author":"Guest EM, Kairalla JA, Devidas M, Hibbitts E, Carroll AJ, Heerema NA, Kubaney HR, August MA, Ramesh S, Yoo B, Farooqi MS, Pauly MG, Wechsler DS, Miles RR, Reid JM, Kihei CD, Gore L, Raetz EA, Hunger SP, Loh ML, Brown PA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38867582"},{"title01":"Genetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemia","title02":"Genetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemia","journal":"Haematologica","issue":"2024 Jun 1;109(6):1629-1630.","author":"Schlenk RF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38832418"},{"title01":"Chimeric antigen receptor therapy for T-cell acute lymphoblastic leukemia: finally catching up with B-cell leukemia?","title02":"Chimeric antigen receptor therapy for T-cell acute lymphoblastic leukemia: finally catching up with B-cell leukemia?","journal":"Haematologica","issue":"2024 Jun 1;109(6):1631-1633.","author":"Beyar-Katz O, Rowe JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38832419"},{"title01":"Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application?","title02":"Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application?","journal":"Haematologica","issue":"2024 Jun 1;109(6):1656-1667.","author":"Naik S, Velasquez MP, Gottschalk S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38832421"},{"title01":"Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia","title02":"Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia","journal":"Haematologica","issue":"2024 Jun 1;109(6):1668-1676.","author":"Lyons KU, Gore L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38832422"},{"title01":"Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia","title02":"Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia","journal":"Haematologica","issue":"2024 Jun 1;109(6):1677-1688.","author":"Oh BLZ, Vinanica N, Wong DMH, Campana D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38832423"},{"title01":"Allogeneic chimeric antigen receptor T cells for children with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","title02":"Allogeneic chimeric antigen receptor T cells for children with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","journal":"Haematologica","issue":"2024 Jun 1;109(6):1689-1699.","author":"Locatelli F, Del Bufalo F, Quintarelli C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38832424"},{"title01":"Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia","title02":"Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia","journal":"Haematologica","issue":"2024 Jun 1;109(6):1700-1712.","author":"Brivio E, Bautista F, Zwaan CM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38832425"},{"title01":"IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia","title02":"<i>IKZF1<\/i> gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia","journal":"Haematologica","issue":"2024 Jun 6. doi: 10.3324\/haematol.2023.284357. Online ahead of print.","author":"Vervoort BMT, Butler M, Gr\u00fcnewald KJT, Schenau DSVI, Tee TM, Lucas L, Huitema ADR, Boer JM, Bornhauser BC, Bourquin JP, Hoogerbrugge PM, Van der Velden VHJ, Kuiper RP, Van der Meer LT, Van Leeuwen FN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38841778"},{"title01":"Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models","title02":"Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models","journal":"Haematologica","issue":"2024 Jun 6. doi: 10.3324\/haematol.2023.284853. Online ahead of print.","author":"Domka K, D\u0105bkowska A, Janowska M, Urba\u0144ska Z, Pastorczak A, Winiarska M, Fidyt K, Lachota M, Patkowska E, S\u0119dek \u0141, Perkowski B, Hunia J, Jakubowska J, Krzymieniewska B, Lech-Mara\u0144da E, M\u0142ynarski W, Szczepa\u0144ski T, Firczuk M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38841802"},{"title01":"Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia","title02":"Upregulation of <i>HOXA3<\/i> by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia","journal":"Br J Haematol","issue":"2024 Jun 12. doi: 10.1111\/bjh.19563. Online ahead of print.","author":"Allen B, Savoy L, Ryabinin P, Bottomly D, Chen R, Goff B, Wang A, McWeeney SK, Zhang H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38867543"},{"title01":"Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia","title02":"Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia","journal":"Br J Haematol","issue":"2024 Jun 4. doi: 10.1111\/bjh.19552. Online ahead of print.","author":"Ronnacker J, Urbahn MA, Reicherts C, Kolloch L, Berning P, Sandmann S, E\u00dfeling E, Call S, Floeth M, Marx J, Albring J, Mikesch JH, Schliemann C, Lenz G, Stelljes M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38831752"},{"title01":"A modern view of LGL leukemia","title02":"A modern view of LGL leukemia","journal":"Blood","issue":"2024 Jun 7:blood.2023021790. doi: 10.1182\/blood.2023021790. Online ahead of print.","author":"Marchand T, Lamy de La Chapelle T, Loughran TP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38848524"},{"title01":"Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab in Relapsed\/Refractory CLL: Phase 1b BRUIN Trial","title02":"Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab in Relapsed\/Refractory CLL: Phase 1b BRUIN Trial","journal":"Blood","issue":"2024 Jun 11:blood.2024024510. doi: 10.1182\/blood.2024024510. Online ahead of print.","author":"Roeker LE, Woyach JA, Cheah CYY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair BC, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38861666"},{"title01":"Awakening your innate power to combat AML","title02":"Awakening your innate power to combat AML","journal":"Blood","issue":"2024 May 30;143(22):2223-2224.","author":"Kang YA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38814654"},{"title01":"Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy","title02":"Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy","journal":"N Engl J Med","issue":"2024 Jun 13;390(22):2047-2060.","author":"Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys PL, Liu CL, Kang X, Olsen MN, Good Z, Dahiya S, Frank MJ, Sahaf B, Mackall CL, Gratzinger D, Diehn M, Alizadeh AA, Miklos DB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38865660"},{"title01":"Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy","title02":"Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy","journal":"N Engl J Med","issue":"2024 Jun 13;390(22):2074-2082.","author":"Ozdemirli M, Loughney TM, Deniz E, Chahine JJ, Albitar M, Pittaluga S, Sadigh S, Armand P, Uren A, Anderson KC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38865661"},{"title01":"Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin","title02":"Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin","journal":"N Engl J Med","issue":"2024 Jun 13;390(22):2129-2130.","author":"Veleanu L, Lamant L, Sibon D; Therapeutic Strategy Project for Adult ALK+ ALCL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38865667"},{"title01":"Ultra-low-dose radiation for gastric MALT lymphoma","title02":"Ultra-low-dose radiation for gastric MALT lymphoma","journal":"Lancet Haematol","issue":"2024 Jun 3:S2352-3026(24)00173-X. doi: 10.1016\/S2352-3026(24)00173-X. Online ahead of print.","author":"Petersen PM, N\u00f8r\u00f8xe DS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38843855"},{"title01":"Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial","title02":"Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial","journal":"Lancet Haematol","issue":"2024 Jun 3:S2352-3026(24)00133-9. doi: 10.1016\/S2352-3026(24)00133-9. Online ahead of print.","author":"Gunther JR, Xu J, Bhutani MS, Strati P, Fang PQ, Wu SY, Dabaja BS, Dong W, Bhosale PR, Flowers CR, Nair R, Malpica Castillo L, Fayad L, Iyer SP, Parmer S, Wang M, Lee HJ, Samaniego F, Westin J, Ahmed S, Nze CC, Jain P, Neelapu SS, Rodriguez MA, Chihara D, Nastoupil LJ, Pinnix CC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38843856"},{"title01":"Primary adrenal insufficiency due to lymphomatoid granulomatosis in a 32-year-old man","title02":"Primary adrenal insufficiency due to lymphomatoid granulomatosis in a 32-year-old man","journal":"Lancet","issue":"2024 Jun 1;403(10442):e33.","author":"Sakuma I, Ishibashi R, Matsue K, Vatner DF, Nakamura Y, Yokote K, Tanaka T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38823995"},{"title01":"Automated Lugano Metabolic Response Assessment in (18)F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on (18)F-Fluorodeoxyglucose-Positron Emission Tomography","title02":"Automated Lugano Metabolic Response Assessment in (18)F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on (18)F-Fluorodeoxyglucose-Positron Emission Tomography","journal":"J Clin Oncol","issue":"2024 Jun 6:JCO2301978. doi: 10.1200\/JCO.23.01978. Online ahead of print.","author":"Jemaa S, Ounadjela S, Wang X, El-Galaly TC, Kostakoglu L, Knapp A, Ku G, Musick L, Sahin D, Wei MC, Yin S, Bengtsson T, De Crespigny A, Carano RAD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38843483"},{"title01":"Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group","title02":"Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group","journal":"Haematologica","issue":"2024 Jun 13. doi: 10.3324\/haematol.2023.284841. Online ahead of print.","author":"Izumiyama K, Inao T, Goto H, Harada S, Senjo H, Suto K, Hashiguchi J, Ogasawara R, Saga T, Igarashi T, Wakasa K, Kasahara I, Takeda Y, Yamaguchi K, Shigematsu A, Takahata M, Fujimoto K, Haseyama Y, Nagashima T, Sakai H, Kakinoki Y, Kurosawa M, Yokota I, Teshima T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38867578"},{"title01":"PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire","title02":"PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire","journal":"Haematologica","issue":"2024 Jun 13. doi: 10.3324\/haematol.2024.284968. Online ahead of print.","author":"Kaphan E, Bettega F, Vallet N, Fegueux N, Robin M, Bazarbachi A, Nguyen S, Beauvais D, Forcade E, De Oca MCM, Devillier R, Chevallier P, Loschi M, Huynh A, Bay JO, Rubio MT, Suarez F, Francois S, Poire X, Contentin N, Desmier D, Charbonnier A, Cornillon J, Chantepie S, Turlure P, Bulabois CE, Michonneau D, Villate A; SFGM-TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38867585"},{"title01":"Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments","title02":"Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments","journal":"Haematologica","issue":"2024 Jun 6. doi: 10.3324\/haematol.2023.284332. Online ahead of print.","author":"Baron M, Labreche K, Veyri M, D\u00e9sir\u00e9 N, Bouzidi A, Seck-Thiam F, Charlotte F, Rousseau A, Morin V, Nakid-Cordero C, Abbar B, Picca A, Le Cann M, Balegroune N, Gauthier N, Theodorou I, Touat M, Morel V, Bielle F, Samri A, Alentorn A, Sanson M, Roos-Weil D, Haioun C, Poullot E, De Septenville AL, Davi F, Guihot A, Boelle PY, Leblond V, Coulet F, Spano JP, Choquet S, Autran B; IDeATIon Study Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38841782"},{"title01":"Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results","title02":"Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results","journal":"Haematologica","issue":"2024 Jun 6. doi: 10.3324\/haematol.2023.283992. Online ahead of print.","author":"Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Maruyama D, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Kato H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38841789"},{"title01":"Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma","title02":"Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma","journal":"Haematologica","issue":"2024 Jun 6. doi: 10.3324\/haematol.2023.284953. Online ahead of print.","author":"Yoshifuji K, Sadato D, Toya T, Motomura Y, Hirama C, Takase H, Yamamoto K, Harada Y, Mori T, Nagao T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38841798"},{"title01":"Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma","title02":"Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma","journal":"Haematologica","issue":"2024 Jun 6. doi: 10.3324\/haematol.2023.284404. Online ahead of print.","author":"Davies N, Francis T, Oldreive C, Azam M, Wilson J, Byrd PJ, Burley M, Sharma-Oates A, Keane P, Alatawi S, Higgs MR, Rudzki Z, Ibrahim M, Perry T, Agathaggelou A, Hewitt AM, Smith E, Bonifer C, O'Connor M, Forment JV, Murray PG, Fennell E, Kelly G, Chang C, Stewart GS, Stankovic T, Kwok M, Taylor AM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38841800"},{"title01":"Long-term cause-specific mortality in adolescent and young adult Hodgkin lymphoma patients treated with contemporary regimens-A nationwide Danish cohort study","title02":"Long-term cause-specific mortality in adolescent and young adult Hodgkin lymphoma patients treated with contemporary regimens-A nationwide Danish cohort study","journal":"Br J Haematol","issue":"2024 Jun 12. doi: 10.1111\/bjh.19586. Online ahead of print.","author":"Rossetti S, Juul SJ, Eriksson F, Warming PE, Glinge C, El-Galaly TC, Haaber Christensen J, Kamper P, de Nully Brown P, Gislason GH, Vestm\u00f8 Maraldo M, Tfelt-Hansen J, Hutchings M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38867552"},{"title01":"Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy","title02":"Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy","journal":"Br J Haematol","issue":"2024 Jun 13. doi: 10.1111\/bjh.19562. Online ahead of print.","author":"Lim YJ, Ward V, Brown A, Phillips E, Kronsteiner B, Malone T, Jennings D, Healy S, Longet S, James T, Thomson P, Farrell L, Oates M, Jackson R, Morrison A, Burns M, Carroll M, Klenerman P, Turtle L, Naisbitt D, Rhodes M, Robinson K, Gatto S, Young M, Linton K, Eyre TA, Eyre DW, Dunachie S, Barnes E, Pettitt A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38867615"},{"title01":"Updated cutaneous T-cell lymphoma TNMB staging criteria fail to identify S\u00e9zary syndrome patients with low blood burden","title02":"Updated cutaneous T-cell lymphoma TNMB staging criteria fail to identify S\u00e9zary syndrome patients with low blood burden","journal":"Blood","issue":"2024 Jun 7:blood.2023023584. doi: 10.1182\/blood.2023023584. Online ahead of print.","author":"Chrisman LP, Trimark PF, Pang Y, Pease DR, Martinez Escala ME, Nguyen W, Fernandez R, Griffin TL, Ayanruoh L, Hooper MJ, Zhou XA, Fu L, Wolniak KL, Guitart J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38848513"},{"title01":"Mantle cell lymphoma with marked plasmacytic differentiation: two contrasting faces","title02":"Mantle cell lymphoma with marked plasmacytic differentiation: two contrasting faces","journal":"Blood","issue":"2024 May 30;143(22):2337.","author":"Apaydin Arikan E, Jaffe ES.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38814655"},{"title01":"Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12) (q36;p13) infant AML","title02":"Backtracking <i>NOM1::ETV6<\/i> fusion to neonatal pathogenesis of t(7;12) (q36;p13) infant AML","journal":"Leukemia","issue":"2024 May 28. doi: 10.1038\/s41375-024-02293-9. Online ahead of print.","author":"Bousquets-Mu\u00f1oz P, Molina O, Varela I, \u00c1lvarez-Eguiluz \u00c1, Fern\u00e1ndez-Mateos J, G\u00f3mez A, S\u00e1nchez EG, Balb\u00edn M, Ruano D, Ram\u00edrez-Orellana M, Puente XS, Men\u00e9ndez P, Velasco-Hernandez T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38806630"},{"title01":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update","title02":"ERIC recommendations for <i>TP53<\/i> mutation analysis in chronic lymphocytic leukemia-2024 update","journal":"Leukemia","issue":"2024 May 16. doi: 10.1038\/s41375-024-02267-x. Online ahead of print.","author":"Malcikova J, Pavlova S, Baliakas P, Chatzikonstantinou T, Tausch E, Catherwood M, Rossi D, Soussi T, Tichy B, Kater AP, Niemann CU, Davi F, Gaidano G, Stilgenbauer S, Rosenquist R, Stamatopoulos K, Ghia P, Pospisilova S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38755420"},{"title01":"To Mars and beyond. Space exploration and space medicine in Leukemia","title02":"To Mars and beyond. Space exploration and space medicine in <i>Leukemia<\/i>","journal":"Leukemia","issue":"2024 May 22. doi: 10.1038\/s41375-024-02286-8. Online ahead of print.","author":"Gale RP, Hochhaus A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38777833"},{"title01":"Niclosamide combined to Azacitidine to target TP53-mutated MDS\/AML cells","title02":"Niclosamide combined to Azacitidine to target <i>TP53<\/i>-mutated MDS\/AML cells","journal":"Leukemia","issue":"2024 May 22. doi: 10.1038\/s41375-024-02281-z. Online ahead of print.","author":"Maslah N, Rety S, Bonnamy M, Aguinaga L, Huynh T, Parietti V, Giraudier S, Fenaux P, Cassinat B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38777834"},{"title01":"CCL22 mutations in large granular lymphocytic leukemia","title02":"<i>CCL22<\/i> mutations in large granular lymphocytic leukemia","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2024.285404. Online ahead of print.","author":"Mizuno Y, Kawakami T, Higano D, Miyairi S, Asakura A, Kawakami F, Sato K, Matsuzawa S, Nishina S, Sakai H, Higuchi Y, Matsuda K, Nakazawa H, Ishida F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813714"},{"title01":"Prognostic impact of 'multi-hit' versus 'single hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases","title02":"Prognostic impact of 'multi-hit' <i>versus<\/i> 'single hit' <i>TP53<\/i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2024.285000. Online ahead of print.","author":"Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813716"},{"title01":"Late-onset NPM1 mutation in a MYC-amplified relapsed \/ refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib","title02":"Late-onset <i>NPM1<\/i> mutation in a MYC-amplified relapsed \/ refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2023.284922. Online ahead of print.","author":"Jaramillo S, Scherer M, Szu-Tu C, Beneyto-Calabuig S, M\u00fcller-Tidow C, Schlenk RF, Hundemer M, Velten L, Pabst C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813731"},{"title01":"Gilteritinib with or without venetoclax for relapsed\/refractory FLT3-mutated acute myeloid leukaemia","title02":"Gilteritinib with or without venetoclax for relapsed\/refractory <i>FLT3<\/i>-mutated acute myeloid leukaemia","journal":"Br J Haematol","issue":"2024 May 23. doi: 10.1111\/bjh.19548. Online ahead of print.","author":"Kugler E, Cohen I, Amitai I, Ram R, Frisch A, Nachmias B, Canaani J, Moshe Y, Krayem B, Aumann S, Henig I, Vainstein V, Shargian L, Ganzel C, Yeshurun M, Levi I, Raanani P, Akria L, Ofran Y, Shimony S, Wolach O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38782575"},{"title01":"A CD10-negative adult B-lymphoblastic leukaemia with amplification of KMT2A without rearrangement: A case report and\u00a0review of the English literature","title02":"A CD10-negative adult B-lymphoblastic leukaemia with amplification of <i>KMT2A<\/i> without rearrangement: A case report and\u00a0review of the English literature","journal":"Br J Haematol","issue":"2024 May 12. doi: 10.1111\/bjh.19520. Online ahead of print.","author":"Wang HY, Louis HMS, Costello CL, Murray SS, Dell'Aquila ML.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38735761"},{"title01":"Personalized therapy guided by single-cell transcriptomic analysis in relapsed and refractory KMT2A::MLLT10 AML with extensive extramedullary infiltration: A case report","title02":"Personalized therapy guided by single-cell transcriptomic analysis in relapsed and refractory <i>KMT2A::MLLT10<\/i> AML with extensive extramedullary infiltration: A case report","journal":"Br J Haematol","issue":"2024 May 13. doi: 10.1111\/bjh.19522. Online ahead of print.","author":"Wang R, Wu Y, Xue R, Shi T, Gu H, Yang Y, Wu W, Yang Y, Sun S, Zhu HH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38740515"},{"title01":"Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed\/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP","title02":"Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed\/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP","journal":"Br J Haematol","issue":"2024 May 27. doi: 10.1111\/bjh.19555. Online ahead of print.","author":"Stewart DA, Kuruvilla J, Lee D, Dudebout JJ, Chua N, Larouche JF, Baetz T, Shafey M, Abdel-Samad N, Robinson S, Fleury I, Fraser G, Skrabek P, Kukreti V, Kelly J, Hay AE, Shepherd LE, Chen BE, Crump M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38802107"},{"title01":"Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease","title02":"Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease","journal":"Br J Haematol","issue":"2024 May 29. doi: 10.1111\/bjh.19458. Online ahead of print.","author":"Alcoceba M, Stewart JP, Garc\u00eda-\u00c1lvarez M, D\u00edaz LG, Jim\u00e9nez C, Medina A, Chill\u00f3n MC, Gazdova J, Blanco O, D\u00edaz FJ, Pe\u00f1arrubia MJ, Fern\u00e1ndez S, Montes C, Cabero A, Caballero MD, Garc\u00eda-Sanz R, Gonz\u00e1lez M, Gonz\u00e1lez D, Tamayo P, Guti\u00e9rrez NC, Garc\u00eda-Sancho AM, Sarasquete ME.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38811363"},{"title01":"Large cell lymphoma through a liquid lens","title02":"Large cell lymphoma through a liquid lens","journal":"Br J Haematol","issue":"2024 May 30. doi: 10.1111\/bjh.19502. Online ahead of print.","author":"Shortt J, Opat S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813654"},{"title01":"Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma","title02":"Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma","journal":"Br J Haematol","issue":"2024 May 16. doi: 10.1111\/bjh.19534. Online ahead of print.","author":"Br\u00f6ckelmann PJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38757338"},{"title01":"HIV and prior exposure to antiretroviral therapy alter tumour composition and tumour: T-cell associations in diffuse large B-cell lymphoma","title02":"HIV and prior exposure to antiretroviral therapy alter tumour composition and tumour: T-cell associations in diffuse large B-cell lymphoma","journal":"Br J Haematol","issue":"2024 May 20. doi: 10.1111\/bjh.19531. Online ahead of print.","author":"Coelho J, Roush SM, Xu AM, Puranam K, Mponda M, Kasonkanji E, Mulenga M, Tomoka T, Galeotti J, Brownlee A, Ghadially H, Damania B, Painschab M, Merchant A, Gopal S, Fedoriw Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38769021"},{"title01":"Biclonal mantle cell lymphoma","title02":"Biclonal mantle cell lymphoma","journal":"Blood","issue":"2024 May 23;143(21):2217.","author":"Jain P, Jelloul FZ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38780924"},{"title01":"CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models","title02":"CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models","journal":"Blood","issue":"2024 May 28:blood.2023022682. doi: 10.1182\/blood.2023022682. Online ahead of print.","author":"Brinkmann BJ, Floerchinger A, Schniederjohann C, Roider T, Coelho M, Mack N, Bruch PM, Liebers N, D\u00f6tsch S, Busch DH, Schmitt M, Neumann F, Roessner PM, Seiffert M, Dietrich S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38805637"},{"title01":"MRD: also for T-lymphoblastic lymphoma","title02":"MRD: also for T-lymphoblastic lymphoma","journal":"Blood","issue":"2024 May 16;143(20):2017-2019.","author":"Ribera JM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38753352"},{"title01":"Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor","title02":"Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor","journal":"Blood","issue":"2024 May 16;143(20):2106.","author":"Yuan CT, Ma WL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38753358"},{"title01":"MRD and EFS in pediatric T-lymphoblastic lymphoma","title02":"MRD and EFS in pediatric T-lymphoblastic lymphoma","journal":"Blood","issue":"2024 May 16;143(20):2111.","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38753360"},{"title01":"Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study","title02":"Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study","journal":"Blood","issue":"2024 May 16:blood.2023023525. doi: 10.1182\/blood.2023023525. Online ahead of print.","author":"Malinverni C, Bernardelli A, Glimelius I, Mirandola M, Ekstrom Smedby KE, Tisi MC, Gin\u00e9 E, Albertsson-Lindblad A, Marin-Niebla AM, Di Rocco A, Moita F, Sciarra R, Ba\u0161i\u0107-Kinda S, Hess GR, Ohler A, Eskelund CW, Re A, Ferrarini I, Kolstad A, R\u00e4ty RK, Quaglia FM, Eyre TA, Scapinello G, Stefani PM, Morello L, Nassi L, Hohaus S, Ragaini S, Zilioli VR, Bruna R, Cocito F, Arcari A, Jerkeman M, Visco C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38754055"},{"title01":"SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma","title02":"SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma","journal":"Blood","issue":"2024 Jan 18;143(19):1953-1964. doi: 10.1182\/blood.2023022241\/2210808\/blood.2023022241.pdf.","author":"Morsy MHA, Lilienthal I, Lord M, Merrien M, Wasik AM, Sureda-G\u00f3mez M, Amador V, Johansson HJ, Lehti\u00f6 J, Garcia-Torre B, Martin-Subero JI, Tsesmetzis N, Tao S, Schinazi RF, Kim B, Sorteberg AL, Wickstr\u00f6m M, Sheppard D, Rassidakis GZ, Taylor IA, Christensson B, Campo E, Herold N, Sander B.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38774451"},{"title01":"Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma","title02":"Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma","journal":"Blood","issue":"2024 May 22:blood.2024023832. doi: 10.1182\/blood.2024023832. Online ahead of print.","author":"Gupta M, Bradley J, Massaad E, Burns E, Georgantas NZ, Maron G, Batten J, Gallagher A, Thierauf J, Nayyar N, Gordon A, Jones S, Pisapia M, Sun Y, Jones PS, Barker FG 2nd, Curry W, Gupta R, Romero J, Wang N, Brastianos P, Martinez-Lage M, Tateishi K, Forst DA, Nahed BV, Batchelor TT, Ritterhouse LL, Iser F, Kessler T, Jordan JT, Dietrich J, Meyerson ML, Cahill DP, Lennerz JK, Carter B, Shankar GM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38776489"},{"title01":"A practical approach to the modern diagnosis and classification of T-and NK-cell lymphomas","title02":"A practical approach to the modern diagnosis and classification of T-and NK-cell lymphomas","journal":"Blood","issue":"2024 May 10:blood.2023021786. doi: 10.1182\/blood.2023021786. Online ahead of print.","author":"de Leval LL, Gaulard P, Dogan A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38728419"},{"title01":"Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA","title02":"Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA","journal":"Lancet Haematol","issue":"2024 May 23:S2352-3026(24)00105-4. doi: 10.1016\/S2352-3026(24)00105-4. Online ahead of print.","author":"Khan MK, Nasti TH, Qian JY, Kleber TJ, Switchenko JM, Kaufman JL, Nooka AJ, Dhodapkar MV, Buchwald ZS, Obiekwe D, Lonial S, Ahmed R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38797190"},{"title01":"LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma","title02":"LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2024.285099. Online ahead of print.","author":"Gong L, Sun H, Liu L, Sun X, Fang T, Yu Z, Sui W, Xu J, Wang T, Feng F, Lei L, Rui W, Liu Y, Zhao X, An G, Lin X, Qiu L, Hao M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813706"},{"title01":"Allogeneic bone marrow transplantation in craniometaphyseal dysplasia","title02":"Allogeneic bone marrow transplantation in craniometaphyseal dysplasia","journal":"Lancet","issue":"2024 May 11;403(10439):1893-1894.","author":"Morelle G, Breton S, Robert MP, Michot C, Boussard C, Cormier-Daire V, Moshous D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38734477"},{"title01":"Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes","title02":"Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes","journal":"J Clin Oncol","issue":"2024 May 9:JCO2302175. doi: 10.1200\/JCO.23.02175. Online ahead of print.","author":"Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Caballero Berrocal JC, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao LP, Campagna A; GenoMed4All, Synthema, GESMD, FISIM, and EuroBloodNET; Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kroger N, Kordasti S, Santini V, Sanz G, Kern W, Platzbecker U, Diez-Campelo M, Maciejewski JP, Ades L, Fenaux P, Haferlach T, Zeidan AM, Castellani G, Komrokji R, Ieva F, Della Porta MG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38723212"},{"title01":"Mucosal-associated invariant T cells are functionally impaired in pediatric and young adult patients following allogeneic hematopoietic stem cell transplantation and their recovery correlates with clinical outcomes","title02":"Mucosal-associated invariant T cells are functionally impaired in pediatric and young adult patients following allogeneic hematopoietic stem cell transplantation and their recovery correlates with clinical outcomes","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2023.284649. Online ahead of print.","author":"Galaverna F, Flamini S, De Luca CD, Pili I, Boccieri E, Benini F, Quagliarella F, Rosignoli C, Rosichini M, Genah S, Catanoso M, Cardinale A, Volpe G, Coccetti M, Pitisci A, Li Pira G, Carta R, Lucarelli B, Del Bufalo F, Bertaina V, Becilli M, Pagliara D, Algeri M, Merli P, Locatelli F, Velardi E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813718"},{"title01":"Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation","title02":"Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2023.284810. Online ahead of print.","author":"Penack O, Peczynski C, Boreland W, Wolff D, Moiseev I, Schoemans H, Koenecke C, Graham C, Peric Z.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813730"},{"title01":"Reduced toxicity conditioning for hematopoietic stem cell transplantation in children with Diamond-Blackfan anemia","title02":"Reduced toxicity conditioning for hematopoietic stem cell transplantation in children with Diamond-Blackfan anemia","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2024.285147. Online ahead of print.","author":"Qudeimat A, Suryaprakash S, Madden R, Srinivasan A, Wlodarski MW, Bhoopalan SV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813735"},{"title01":"Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed\/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP","title02":"Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed\/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP","journal":"Br J Haematol","issue":"2024 May 27. doi: 10.1111\/bjh.19555. Online ahead of print.","author":"Stewart DA, Kuruvilla J, Lee D, Dudebout JJ, Chua N, Larouche JF, Baetz T, Shafey M, Abdel-Samad N, Robinson S, Fleury I, Fraser G, Skrabek P, Kukreti V, Kelly J, Hay AE, Shepherd LE, Chen BE, Crump M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38802107"},{"title01":"Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group","title02":"Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group","journal":"Br J Haematol","issue":"2024 May 27. doi: 10.1111\/bjh.19535. Online ahead of print.","author":"Pichler H, Sedlacek P, Meisel R, Beier R, Faraci M, Kalwak K, Ifversen M, M\u00fcller I, Stein J, Vettenranta K, Kropshofer G, Kolenova A, Karlhuber S, Glogova E, Poetschger U, Peters C, Suttorp M, Matthes-Leodolter S, Balduzzi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38803040"},{"title01":"Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group","title02":"Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group","journal":"Br J Haematol","issue":"2024 May 29. doi: 10.1111\/bjh.19518. Online ahead of print.","author":"Jim\u00e9nez-Vicente C, Charry P, Casta\u00f1o-Diez S, Guijarro F, L\u00f3pez-Guerra M, P\u00e9rez-Valencia AI, Martinez-Roca A, Cort\u00e9s-Bullich A, Mun\u00e1rriz D, Solano MT, Rosi\u00f1ol L, Carreras E, Urbano-Ispizua \u00c1, Fern\u00e1ndez-Avil\u00e9s F, Martinez C, Su\u00e1rez-Lled\u00f3 M, D\u00edaz-Bey\u00e1 M, Rovira M, Salas MQ, Esteve J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38811025"},{"title01":"Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03","title02":"Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03","journal":"Br J Haematol","issue":"2024 May 29. doi: 10.1111\/bjh.19570. Online ahead of print.","author":"Perrot A, Roussel M, Lauwers-Cances V, Hulin C, Leleu X, Touzeau C, Facon T, Mariette C, Schiano JM, Gay J, Montes L, Ranta D, Huguet A, Wuill\u00e8me S, Dejoie T, Devlamynck L, Corre J, Avet-Loiseau H, Moreau P, Attal M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38811169"},{"title01":"Transplant in AML: just follow the NPM1 guide!","title02":"Transplant in AML: just follow the NPM1 guide!","journal":"Blood","issue":"2024 May 9;143(19):1881-1882.","author":"R\u00e9cher C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38722660"},{"title01":"Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?","title02":"Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?","journal":"Blood","issue":"2024 May 10:blood.2023022273. doi: 10.1182\/blood.2023022273. Online ahead of print.","author":"Scheid C, Eikema DJ, Van Gelder M, Salmenniemi U, Maertens J MD, Passweg JR, Blaise D, Byrne JL, Kroeger N, Sockel K, Chevallier P, Bourhis JH, Cornelissen JJ, Sengeloev H, Finke J, Snowden JA, Gedde-Dahl T, Cornillon J, Schanz U, Patel A, Koster L, de Wreede LC, Hayden PJ, Raj K, Drozd-Sokolowska J, Gurnari C, Onida F, McLornan DP, Robin M, Yakoub-Agha I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38728380"},{"title01":"How I manage iron overload in the hemopoietic cell transplantation setting","title02":"How I manage iron overload in the hemopoietic cell transplantation setting","journal":"Blood","issue":"2024 May 10:blood.2023022500. doi: 10.1182\/blood.2023022500. Online ahead of print.","author":"Angelucci E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38728389"},{"title01":"Tricking the Trickster: Precision Medicine Approaches to Counteract Leukemia Immune Escape after Transplant","title02":"Tricking the Trickster: Precision Medicine Approaches to Counteract Leukemia Immune Escape after Transplant","journal":"Blood","issue":"2024 May 10:blood.2023019962. doi: 10.1182\/blood.2023019962. Online ahead of print.","author":"Tameni A, Toffalori C, Vago L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38728431"},{"title01":"Prof. Constance Jean Eaves: Doyenne of Stem Cells. May 22, 1944 &#8211; March 7, 2024","title02":"Prof. Constance Jean Eaves: Doyenne of Stem Cells. May 22, 1944 &#8211; March 7, 2024","journal":"Leukemia","issue":"2024 May 27. doi: 10.1038\/s41375-024-02289-5. Online ahead of print.","author":"Gale RP, Hochhaus A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38802586"},{"title01":"TIF1\u03b2 activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia","title02":"TIF1\u03b2 activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia","journal":"Leukemia","issue":"2024 May 11. doi: 10.1038\/s41375-024-02276-w. Online ahead of print.","author":"Morii M, Kubota S, Iimori M, Yokomizo-Nakano T, Hamashima A, Bai J, Nishimura A, Tasaki M, Ando Y, Araki K, Sashida G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38734786"},{"title01":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","title02":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","journal":"Lancet Haematol","issue":"2024 Jun;11(6):e448-e458.","author":"Pagliuca S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38796194"},{"title01":"Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes","title02":"Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes","journal":"J Clin Oncol","issue":"2024 May 9:JCO2302175. doi: 10.1200\/JCO.23.02175. Online ahead of print.","author":"Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Caballero Berrocal JC, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao LP, Campagna A; GenoMed4All, Synthema, GESMD, FISIM, and EuroBloodNET; Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kroger N, Kordasti S, Santini V, Sanz G, Kern W, Platzbecker U, Diez-Campelo M, Maciejewski JP, Ades L, Fenaux P, Haferlach T, Zeidan AM, Castellani G, Komrokji R, Ieva F, Della Porta MG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38723212"},{"title01":"Mucosal-associated invariant T cells are functionally impaired in pediatric and young adult patients following allogeneic hematopoietic stem cell transplantation and their recovery correlates with clinical outcomes","title02":"Mucosal-associated invariant T cells are functionally impaired in pediatric and young adult patients following allogeneic hematopoietic stem cell transplantation and their recovery correlates with clinical outcomes","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2023.284649. Online ahead of print.","author":"Galaverna F, Flamini S, De Luca CD, Pili I, Boccieri E, Benini F, Quagliarella F, Rosignoli C, Rosichini M, Genah S, Catanoso M, Cardinale A, Volpe G, Coccetti M, Pitisci A, Li Pira G, Carta R, Lucarelli B, Del Bufalo F, Bertaina V, Becilli M, Pagliara D, Algeri M, Merli P, Locatelli F, Velardi E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813718"},{"title01":"Reduced toxicity conditioning for hematopoietic stem cell transplantation in children with Diamond-Blackfan anemia","title02":"Reduced toxicity conditioning for hematopoietic stem cell transplantation in children with Diamond-Blackfan anemia","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2024.285147. Online ahead of print.","author":"Qudeimat A, Suryaprakash S, Madden R, Srinivasan A, Wlodarski MW, Bhoopalan SV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813735"},{"title01":"Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed\/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP","title02":"Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed\/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP","journal":"Br J Haematol","issue":"2024 May 27. doi: 10.1111\/bjh.19555. Online ahead of print.","author":"Stewart DA, Kuruvilla J, Lee D, Dudebout JJ, Chua N, Larouche JF, Baetz T, Shafey M, Abdel-Samad N, Robinson S, Fleury I, Fraser G, Skrabek P, Kukreti V, Kelly J, Hay AE, Shepherd LE, Chen BE, Crump M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38802107"},{"title01":"Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group","title02":"Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group","journal":"Br J Haematol","issue":"2024 May 27. doi: 10.1111\/bjh.19535. Online ahead of print.","author":"Pichler H, Sedlacek P, Meisel R, Beier R, Faraci M, Kalwak K, Ifversen M, M\u00fcller I, Stein J, Vettenranta K, Kropshofer G, Kolenova A, Karlhuber S, Glogova E, Poetschger U, Peters C, Suttorp M, Matthes-Leodolter S, Balduzzi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38803040"},{"title01":"Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group","title02":"Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group","journal":"Br J Haematol","issue":"2024 May 29. doi: 10.1111\/bjh.19518. Online ahead of print.","author":"Jim\u00e9nez-Vicente C, Charry P, Casta\u00f1o-Diez S, Guijarro F, L\u00f3pez-Guerra M, P\u00e9rez-Valencia AI, Martinez-Roca A, Cort\u00e9s-Bullich A, Mun\u00e1rriz D, Solano MT, Rosi\u00f1ol L, Carreras E, Urbano-Ispizua \u00c1, Fern\u00e1ndez-Avil\u00e9s F, Martinez C, Su\u00e1rez-Lled\u00f3 M, D\u00edaz-Bey\u00e1 M, Rovira M, Salas MQ, Esteve J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38811025"},{"title01":"IL-1 in Aging and Pathologies of Hematopoietic Stem Cells","title02":"IL-1 in Aging and Pathologies of Hematopoietic Stem Cells","journal":"Blood","issue":"2024 May 23:blood.2023023105. doi: 10.1182\/blood.2023023105. Online ahead of print.","author":"Manz MG, Caiado F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38781562"},{"title01":"Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of cell cycle","title02":"Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of cell cycle","journal":"Blood","issue":"2024 May 28:blood.2023021426. doi: 10.1182\/blood.2023021426. Online ahead of print.","author":"Johnson CS, Williams MJ, Sham K, Belluschi S, Ma W, Wang X, Lau WW, Kaufmann K, Krivdova G, Calderbank EF, Mende N, McLeod J, Mantica G, Li J, Grey-Wilson C, Drakopoulos M, Basheer S, Sinha S, Diamanti E, Basford C, Wilson NK, Howe SJ, Dick JE, Gottgens B, Green AR, Francis N, Laurenti E PhD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38805639"},{"title01":"How I Use Next Generation Sequencing-MRD to Plan Approach and Prevent Relapse after HCT for Children and Adults with ALL","title02":"How I Use Next Generation Sequencing-MRD to Plan Approach and Prevent Relapse after HCT for Children and Adults with ALL","journal":"Blood","issue":"2024 May 10:blood.2023023699. doi: 10.1182\/blood.2023023699. Online ahead of print.","author":"Muffly L, Liang EC, Dolan JG, Pulsipher MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38728375"},{"title01":"How I manage iron overload in the hemopoietic cell transplantation setting","title02":"How I manage iron overload in the hemopoietic cell transplantation setting","journal":"Blood","issue":"2024 May 10:blood.2023022500. doi: 10.1182\/blood.2023022500. Online ahead of print.","author":"Angelucci E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38728389"},{"title01":"The effects of upward revision of haemoglobin thresholds for anaemia in blood donations","title02":"The effects of upward revision of haemoglobin thresholds for anaemia in blood donations","journal":"Lancet Haematol","issue":"2024 Jun;11(6):e396-e397.","author":"Sato T, Tsuno NH, Yanagisawa R, Fujiwara SI.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38796185"},{"title01":"Eltrombopag-cyclosporin A in treating severe aplastic anaemia","title02":"Eltrombopag-cyclosporin A in treating severe aplastic anaemia","journal":"Lancet Haematol","issue":"2024 Jun;11(6):e397.","author":"Sathiamoorthy KS, Manikandan S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38796186"},{"title01":"The effects of upward revision of haemoglobin thresholds for anaemia in blood donations &#8211; Authors&#8217; reply","title02":"The effects of upward revision of haemoglobin thresholds for anaemia in blood donations &#8211; Authors&#8217; reply","journal":"Lancet Haematol","issue":"2024 Jun;11(6):e397.","author":"Fielding KL, Braat S, Pasricha SR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38796187"},{"title01":"Eltrombopag-cyclosporin A in treating severe aplastic anaemia &#8211; Authors&#8217; reply","title02":"Eltrombopag-cyclosporin A in treating severe aplastic anaemia &#8211; Authors&#8217; reply","journal":"Lancet Haematol","issue":"2024 Jun;11(6):e398.","author":"Scheinberg P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38796188"},{"title01":"Infrequent fractures and resilient bone mineral density: bone health in patients with Fanconi anemia","title02":"Infrequent fractures and resilient bone mineral density: bone health in patients with Fanconi anemia","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2024.285612. Online ahead of print.","author":"Koo J, Howell JC, Hornung L, Sabulski A, Mehta PA, Davies SM, Myers KC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813733"},{"title01":"Reduced toxicity conditioning for hematopoietic stem cell transplantation in children with Diamond-Blackfan anemia","title02":"Reduced toxicity conditioning for hematopoietic stem cell transplantation in children with Diamond-Blackfan anemia","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2024.285147. Online ahead of print.","author":"Qudeimat A, Suryaprakash S, Madden R, Srinivasan A, Wlodarski MW, Bhoopalan SV.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813735"},{"title01":"Whole-blood transcriptome analysis reveals distinct gene expression signatures in paediatric patients with sickle cell anaemia before and after exercise","title02":"Whole-blood transcriptome analysis reveals distinct gene expression signatures in paediatric patients with sickle cell anaemia before and after exercise","journal":"Br J Haematol","issue":"2024 May 20. doi: 10.1111\/bjh.19533. Online ahead of print.","author":"Plaza-Florido A, Liem RI, Haddad F, Radom-Aizik S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38768976"},{"title01":"Integrated proteogenomic analysis for inherited bone marrow failure syndrome","title02":"Integrated proteogenomic analysis for inherited bone marrow failure syndrome","journal":"Leukemia","issue":"2024 May 13. doi: 10.1038\/s41375-024-02263-1. Online ahead of print.","author":"Wakamatsu M, Muramatsu H, Sato H, Ishikawa M, Konno R, Nakajima D, Hamada M, Okuno Y, Kawashima Y, Hama A, Ito M, Iwafuchi H, Takahashi Y, Ohara O.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38740980"},{"title01":"Genomic insights into inherited bone marrow failure syndromes in a Korean population","title02":"Genomic insights into inherited bone marrow failure syndromes in a Korean population","journal":"Br J Haematol","issue":"2024 May 12. doi: 10.1111\/bjh.19509. Online ahead of print.","author":"Lee JM, Kim HS, Yoo J, Lee J, Ahn A, Cho H, Han EH, Jung J, Yoo JW, Kim S, Lee JW, Cho B, Chung NG, Kim M, Kim Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38735735"},{"title01":"Cognitive impairment among patients with chronic immune thrombocytopenia","title02":"Cognitive impairment among patients with chronic immune thrombocytopenia","journal":"Br J Haematol","issue":"2024 May 9. doi: 10.1111\/bjh.19495. Online ahead of print.","author":"Kuter DJ, Khan U, Maruff P, Daak A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38724473"},{"title01":"TIF1\u03b2 activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia","title02":"TIF1\u03b2 activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia","journal":"Leukemia","issue":"2024 May 11. doi: 10.1038\/s41375-024-02276-w. Online ahead of print.","author":"Morii M, Kubota S, Iimori M, Yokomizo-Nakano T, Hamashima A, Bai J, Nishimura A, Tasaki M, Ando Y, Araki K, Sashida G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38734786"},{"title01":"Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis","title02":"Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis","journal":"Leukemia","issue":"2024 May 11. doi: 10.1038\/s41375-024-02268-w. Online ahead of print.","author":"Awada H, Durmaz A, Kewan T, Ullah F, Dima D, Awada H, Pagliuca S, Meggendorfer M, Haferlach T, Gurnari C, Visconte V, Maciejewski JP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38734787"},{"title01":"DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients","title02":"DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients","journal":"Leukemia","issue":"2024 May 11. doi: 10.1038\/s41375-024-02269-9. Online ahead of print.","author":"Karami A, Skorski T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38734788"},{"title01":"Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols","title02":"Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols","journal":"Leukemia","issue":"2024 May 14. doi: 10.1038\/s41375-024-02264-0. Online ahead of print.","author":"Neumann M, Beder T, Bastian L, H\u00e4nzelmann S, Bultmann M, Wolgast N, Hartmann A, Trautmann H, Ortiz-Tanchez J, Schlee C, Schroeder M, Fransecky L, Vosberg S, Fiedler W, Alakel N, Heberling L, Kondakci M, Starck M, Schwartz S, Raffel S, M\u00fcller-Tidow C, Schneller F, Reichle A, Burmeister T, Greif PA, Br\u00fcggemann M, G\u00f6kbuget N, Baldus CD.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38744920"},{"title01":"Refining risk stratification to improve prognosis in juvenile myelomonocytic leukemia","title02":"Refining risk stratification to improve prognosis in juvenile myelomonocytic leukemia","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2024.285326. Online ahead of print.","author":"Nunn JL, Fraser CJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813703"},{"title01":"The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: final analysis including overall survival","title02":"The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: final analysis including overall survival","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2024.285043. Online ahead of print.","author":"Danilov AV, Flinn IW, Davids MS, Gregory B, Bentur O, Sidransky D, Brown JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813715"},{"title01":"Single-cell CRISPR screening characterizes transcriptional deregulation in T-cell acute lymphoblastic leukemia","title02":"Single-cell CRISPR screening characterizes transcriptional deregulation in T-cell acute lymphoblastic leukemia","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2023.284901. Online ahead of print.","author":"Meyers S, Gielen O, Cools J, Demeyer S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813729"},{"title01":"The glutamate\/aspartate transporter EAAT1 is crucial for T-cell acute lymphoblastic leukemia proliferation and survival","title02":"The glutamate\/aspartate transporter EAAT1 is crucial for T-cell acute lymphoblastic leukemia proliferation and survival","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2023.283471. Online ahead of print.","author":"Stanulovi\u0107 VS, Al Omair S, Reed MAC, Roberts J, Potluri S, Fulton-Ward T, Gudgeon N, Bishop EL, Roels J, Perry TA, Sarkar S, Pratt G, Taghon T, Dimeloe S, G\u00fcnther UL, Ludwig C, Hoogenkamp M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813748"},{"title01":"Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","title02":"Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","journal":"Haematologica","issue":"2024 May 23. doi: 10.3324\/haematol.2023.284950. Online ahead of print.","author":"Gibson A, Nunez C, Robusto L, Kammerer B, Garcia M, Roth M, Sheth R, Tewari P, Hittle A, Toepfer L, Torres R, Short NJ, Jabbour E, Jain N, Cuglievan B, McCall D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38779719"},{"title01":"Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group","title02":"Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group","journal":"Br J Haematol","issue":"2024 May 27. doi: 10.1111\/bjh.19535. Online ahead of print.","author":"Pichler H, Sedlacek P, Meisel R, Beier R, Faraci M, Kalwak K, Ifversen M, M\u00fcller I, Stein J, Vettenranta K, Kropshofer G, Kolenova A, Karlhuber S, Glogova E, Poetschger U, Peters C, Suttorp M, Matthes-Leodolter S, Balduzzi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38803040"},{"title01":"Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia","title02":"Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"2024 May 29. doi: 10.1111\/bjh.19551. Online ahead of print.","author":"Othman T, Koller P, Pourhassan H, Agrawal V, Ngo D, Tinajero J, Ali H, Cai JL, Mei M, Aribi A, Stein AS, Marcucci G, Forman SJ, Pullarkat V, Aldoss I.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38808512"},{"title01":"Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group","title02":"Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group","journal":"Br J Haematol","issue":"2024 May 29. doi: 10.1111\/bjh.19518. Online ahead of print.","author":"Jim\u00e9nez-Vicente C, Charry P, Casta\u00f1o-Diez S, Guijarro F, L\u00f3pez-Guerra M, P\u00e9rez-Valencia AI, Martinez-Roca A, Cort\u00e9s-Bullich A, Mun\u00e1rriz D, Solano MT, Rosi\u00f1ol L, Carreras E, Urbano-Ispizua \u00c1, Fern\u00e1ndez-Avil\u00e9s F, Martinez C, Su\u00e1rez-Lled\u00f3 M, D\u00edaz-Bey\u00e1 M, Rovira M, Salas MQ, Esteve J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38811025"},{"title01":"Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease","title02":"Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease","journal":"Br J Haematol","issue":"2024 May 9. doi: 10.1111\/bjh.19519. Online ahead of print.","author":"Jen WY, Kantarjian H, Kadia TM, DiNardo CD, Issa GC, Short NJ, Yilmaz M, Borthakur G, Ravandi F, Daver NG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38724457"},{"title01":"Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia","title02":"Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"2024 May 12. doi: 10.1111\/bjh.19524. Online ahead of print.","author":"Dourthe ME, Yakouben K, David A, Thouvenin S, Chaillou D, Caillat-Zucman S, Cuffel A, Tardy C, Lainey E, Caye-Eude A, Arfeuille C, Delaugerre C, Chaix-Baudier ML, Naudin J, Auvin S, Bergaoui K, Merlat-Guitard AI, De Jorna R, Mebarki M, Dalle JH, Baruchel A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38735758"},{"title01":"CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models","title02":"CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models","journal":"Blood","issue":"2024 May 28:blood.2023022682. doi: 10.1182\/blood.2023022682. Online ahead of print.","author":"Brinkmann BJ, Floerchinger A, Schniederjohann C, Roider T, Coelho M, Mack N, Bruch PM, Liebers N, D\u00f6tsch S, Busch DH, Schmitt M, Neumann F, Roessner PM, Seiffert M, Dietrich S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38805637"},{"title01":"Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia","title02":"Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia","journal":"Blood","issue":"2024 May 28:blood.2024023890. doi: 10.1182\/blood.2024023890. Online ahead of print.","author":"Koury LCA, Kim HT, Undurraga MS, Navarro-Cabrera JR, Salinas V, Muxi P, Melo RAM, Gloria ABF, Pagnano KBB, Nunes EC, Bittencourt RI, Rojas N, Quintana Truyenque SM, Ayala-Lugo AI Dr, Oliver AC, de Figueiredo-Pontes LL, Traina F, Moreira F, Fagundes EM, Duarte BKL, Mora-Alferez AP, Ortiz P, Untama JL, Tallman MS, Ribeiro RC, Ganser A, Dillon RJ, Valk PJM, Sanz MA, L\u00f6wenberg B, Berliner N, Rego EM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38805638"},{"title01":"Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib","title02":"Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib","journal":"Blood","issue":"2024 May 16:blood.2023023659. doi: 10.1182\/blood.2023023659. Online ahead of print.","author":"Woyach JA, Jones D, Jurczak W, Robak T Prof, Illes A, Kater AP, Ghia P, Byrd JC, Seymour JF, Long S, Mohamed N, Benrashid S, Lai TH, De Jesus G, Lai R, de Bruin G, Rule S, Munugalavadla V.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38754046"},{"title01":"Targeting the tumor microenvironment for treating double refractory chronic lymphocytic leukemia","title02":"Targeting the tumor microenvironment for treating double refractory chronic lymphocytic leukemia","journal":"Blood","issue":"2024 May 22:blood.2023022861. doi: 10.1182\/blood.2023022861. Online ahead of print.","author":"Lewis RI, Vom Stein AF, Hallek MJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38776510"},{"title01":"CD8+ T-cell Differentiation and Dysfunction Inform Treatment Response in Acute Myeloid Leukemia","title02":"CD8+ T-cell Differentiation and Dysfunction Inform Treatment Response in Acute Myeloid Leukemia","journal":"Blood","issue":"2024 May 22:blood.2023021680. doi: 10.1182\/blood.2023021680. Online ahead of print.","author":"Mazziotta F, Biavati L, Rimando JC, Rutella S, Borcherding N, Parbhoo S, Mukhopadhyay R, Knaus HA, Valent P, Hackl H, Borrello I, Blazar BR, Hatzi K, Gojo I, Luznik L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38776511"},{"title01":"PIKing the right target in AML","title02":"PIKing the right target in AML","journal":"Blood","issue":"2024 May 9;143(19):1884-1885.","author":"Sung PJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38722658"},{"title01":"Transplant in AML: just follow the NPM1 guide!","title02":"Transplant in AML: just follow the NPM1 guide!","journal":"Blood","issue":"2024 May 9;143(19):1881-1882.","author":"R\u00e9cher C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38722660"},{"title01":"Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia","title02":"Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia","journal":"Blood","issue":"2024 May 10:blood.2023023313. doi: 10.1182\/blood.2023023313. Online ahead of print.","author":"Le RQ, Przepiorka D, Chen H, Shen YL, Pulte ED, Norsworthy KJ, Theoret MR, De Claro RA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38728428"},{"title01":"Tricking the Trickster: Precision Medicine Approaches to Counteract Leukemia Immune Escape after Transplant","title02":"Tricking the Trickster: Precision Medicine Approaches to Counteract Leukemia Immune Escape after Transplant","journal":"Blood","issue":"2024 May 10:blood.2023019962. doi: 10.1182\/blood.2023019962. Online ahead of print.","author":"Tameni A, Toffalori C, Vago L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38728431"},{"title01":"Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML","title02":"Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML","journal":"Blood","issue":"2024 May 15:blood.2024024264. doi: 10.1182\/blood.2024024264. Online ahead of print.","author":"Cook JA, Lott L, Perry J ASCP (MLS), Eckel AM, Xu D, Hudson CA, Wells DA, Loken MR, Menssen AJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38749014"},{"title01":"Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK\/T-cell lymphoma","title02":"Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK\/T-cell lymphoma","journal":"Leukemia","issue":"2024 May 23. doi: 10.1038\/s41375-024-02266-y. Online ahead of print.","author":"Li Y, Chen K, Chen B, Zeng R, He Y, Wang C, Zhong M, Liu X, Chen X, Xiao L, Zhou H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38783159"},{"title01":"Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis","title02":"Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis","journal":"Leukemia","issue":"2024 May 15. doi: 10.1038\/s41375-024-02242-6. Online ahead of print.","author":"Wang TP, Ahn KW, Shadman M, Kaur M, Ahmed N, Bacher U, Cerny J, Chen A, Epperla N, Frigault M, Grover N, Haverkos B, Hill B, Hossain N, Iqbal M, Jain T, Krem MM, Maakaron J, Modi D, Alhaj Moustafa M, Riedell P, Savani B, Sica RA, Sureda A, Wudhikarn K, Herrera AF, Sauter C, Hamadani M, Jimenez Jimenez A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38750138"},{"title01":"Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma","title02":"Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma","journal":"Leukemia","issue":"2024 May 15. doi: 10.1038\/s41375-024-02279-7. Online ahead of print.","author":"Liang JH, Wu YF, Shen HR, Li Y, Liang JH, Gao R, Hua W, Shang CY, Du KX, Xing TY, Zhang XY, Wang CX, Zhu LQ, Shao YW, Li JY, Wu JZ, Yin H, Wang L, Xu W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38750139"},{"title01":"Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study","title02":"Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study","journal":"Lancet Haematol","issue":"2024 Jun;11(6):e406-e414.","author":"Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, Andr\u00e9 M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, Lemonnier F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38796193"},{"title01":"Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?","title02":"Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2022.282362. Online ahead of print.","author":"Ghione P, Salles G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813707"},{"title01":"The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: final analysis including overall survival","title02":"The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: final analysis including overall survival","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2024.285043. Online ahead of print.","author":"Danilov AV, Flinn IW, Davids MS, Gregory B, Bentur O, Sidransky D, Brown JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813715"},{"title01":"Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets","title02":"Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets","journal":"Haematologica","issue":"2024 May 30. doi: 10.3324\/haematol.2023.284448. Online ahead of print.","author":"Stephan P, Perrot J, Voisin A, Barbery M, Andrieu T, Grimont M, Caramel J, Bardou M, Tondeur G, Missiaglia E, Gaulard P, Lemmonier F, De Leval L, Bachy E, Sujobert P, Genestier L, Traverse-Glehen A, Grinberg-Bleyer Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38813724"},{"title01":"Checkpoint inhibition enhances cell contacts between CD4+ T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma","title02":"Checkpoint inhibition enhances cell contacts between CD4+ T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma","journal":"Haematologica","issue":"2024 May 23. doi: 10.3324\/haematol.2023.284512. Online ahead of print.","author":"Yadigaroglu K, Scharf S, Gretser S, Sch\u00e4fer H, Deli ASS, Loth AG, Yegoryan H, Schmitz R, Donnadieu E, Hansmann ML, Hartmann S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38779721"},{"title01":"B-cell maturation antigen-directed bispecific antibodies in plasmablastic lymphoma","title02":"B-cell maturation antigen-directed bispecific antibodies in plasmablastic lymphoma","journal":"Br J Haematol","issue":"2024 May 23. doi: 10.1111\/bjh.19571. Online ahead of print.","author":"Hofer KD, Wolfensberger N, Bachofner A, Schneidawind C, St\u00fchler C, B\u00fchler MM, Abela IA, M\u00fcller NJ, Zenz T, Manz MG, R\u00f6sler W, Khanna N, Schneidawind D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38782604"},{"title01":"Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia\/lymphoma: Experience from a tertiary care centre in South India","title02":"Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia\/lymphoma: Experience from a tertiary care centre in South India","journal":"Br J Haematol","issue":"2024 May 26. doi: 10.1111\/bjh.19559. Online ahead of print.","author":"Rupakumar T, Sankar A, Vijayasekharan K, Varikkattu Rajendran P, Chellapan Sojamani G, Rajeswari B, Nair M, Anandarajan R, Dennis D, Thankamony P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38797523"},{"title01":"Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis","title02":"Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis","journal":"Br J Haematol","issue":"2024 May 26. doi: 10.1111\/bjh.19569. Online ahead of print.","author":"Epperla N, Hashmi H, Ahn KW, Allbee-Johnson M, Chen AI, Wirk B, Kanakry JA, Lekakis L, Kharfan-Dabaja MA, Scordo M, Riedell PA, Jain T, Shadman M, Sauter C, Hamadani M, Herrera AF, Ahmed S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38797526"},{"title01":"Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma","title02":"Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma","journal":"Br J Haematol","issue":"2024 May 26. doi: 10.1111\/bjh.19521. Online ahead of print.","author":"Othman T, Baird JH, Pak S, Mei M, Herrera AF, Mansour J, Shouse G, Sahebi F, Spielberger R, Cai JL, Farol L, Godfrey J, Kallam A, Phillips T, Popplewell L, Siddiqi T, Forman S, Budde LE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38797530"},{"title01":"Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03","title02":"Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03","journal":"Br J Haematol","issue":"2024 May 29. doi: 10.1111\/bjh.19570. Online ahead of print.","author":"Perrot A, Roussel M, Lauwers-Cances V, Hulin C, Leleu X, Touzeau C, Facon T, Mariette C, Schiano JM, Gay J, Montes L, Ranta D, Huguet A, Wuill\u00e8me S, Dejoie T, Devlamynck L, Corre J, Avet-Loiseau H, Moreau P, Attal M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38811169"},{"title01":"French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry","title02":"French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry","journal":"Br J Haematol","issue":"2024 May 15. doi: 10.1111\/bjh.19505. Online ahead of print.","author":"Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, Touzeau C, Leleu X, Moya N, Harel S, Perrot A, Bories P, Vincent L, Lamure S, Mohty M, Malard F, Manier S, Yakoub-Agha I, Schiano De Colella JM, Brisou G, Talbot A, Decaux O, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Moreau P, Arnulf B; Intergroupe Francophone du My\u00e9lome.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38747092"},{"title01":"How can we stamp out high-risk myeloma?","title02":"How can we stamp out high-risk myeloma?","journal":"Blood","issue":"2024 May 16;143(20):2015-2016.","author":"Banerjee R, Mikhael JR.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38753353"},{"title01":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma","title02":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma","journal":"Blood","issue":"2024 May 20:blood.2024024371. doi: 10.1182\/blood.2024024371. Online ahead of print.","author":"Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, Einsele H, Goldschmidt H, Knop S, Li C, Mellqvist UH, McFadden I, Oprea C, Ross JA, Talpes M, Hydren J, Ahlstrom J, Kazandjian D, Weinhold N, Zhang R, Stetler-Stevenson M, Marti GE MD, PhD, Devlin SM.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38768337"},{"title01":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","title02":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","journal":"Blood","issue":"2024 May 10:blood.2023023557. doi: 10.1182\/blood.2023023557. Online ahead of print.","author":"Firestone RS, Socci ND, Shekarkhand T, Zhu M, Ge Qin W, Hultcrantz ML, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt SA, Murata K, Usmani SZ, Chung DJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38728378"},{"title01":"The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma","title02":"The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma","journal":"Blood","issue":"2024 May 10:blood.2024024299. doi: 10.1182\/blood.2024024299. Online ahead of print.","author":"Cirrincione AM, Poos AM, Ziccheddu B, Kaddoura M, Baertsch MA, Maclachlan KH, Chojnacka M, Diamond BT, John L, Reichert P, Huhn S, Blaney P, Gagler DC, Rippe K, Zhang Y, Dogan A, Lesokhin AM, Davies FE, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Usmani SZ, Landgren O, Raab MS, Weinhold N, Maura F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38728430"},{"title01":"Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis","title02":"Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis","journal":"Leukemia","issue":"2024 May 15. doi: 10.1038\/s41375-024-02242-6. Online ahead of print.","author":"Wang TP, Ahn KW, Shadman M, Kaur M, Ahmed N, Bacher U, Cerny J, Chen A, Epperla N, Frigault M, Grover N, Haverkos B, Hill B, Hossain N, Iqbal M, Jain T, Krem MM, Maakaron J, Modi D, Alhaj Moustafa M, Riedell P, Savani B, Sica RA, Sureda A, Wudhikarn K, Herrera AF, Sauter C, Hamadani M, Jimenez Jimenez A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38750138"},{"title01":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","title02":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","journal":"Lancet Haematol","issue":"2024 Jun;11(6):e448-e458.","author":"Pagliuca S, Schmid C, Santoro N, Simonetta F, Battipaglia G, Guillaume T, Greco R, Onida F, S\u00e1nchez-Ortega I, Yakoub-Agha I, Kuball J, Hazenberg MD, Ruggeri A; Practice Harmonization and Guidelines Committee and the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation (EBMT).","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38796194"},{"title01":"Challenges in undertaking research in transplantation","title02":"Challenges in undertaking research in transplantation","journal":"Lancet","issue":"2024 May 21:S0140-6736(24)00931-0. doi: 10.1016\/S0140-6736(24)00931-0. Online ahead of print.","author":"Oniscu GC, Rockell K, Martin DE.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38788740"},{"title01":"Recommendations from the AML molecular MRD expert advisory board","title02":"Recommendations from the AML molecular MRD expert advisory board","journal":"Leukemia","issue":"2024 May 23. doi: 10.1038\/s41375-024-02275-x. Online ahead of print.","author":"Scott S, Devonshire A, Dillon R, Thiede C, Cross NCP, White HE, Lo Cascio L, Mokretar K, Potter N, Hourigan CS, Radich J, Corner A, Laloux V, Halliday G, Dilks D, Morrison T, Gilmour K, Cartwright A, Whitby L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38783160"},{"title01":"Inhibition of NOTCH4 sensitizes FLT3\/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition","title02":"Inhibition of NOTCH4 sensitizes FLT3\/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition","journal":"Leukemia","issue":"2024 May 29. doi: 10.1038\/s41375-024-02292-w. Online ahead of print.","author":"Zhu R, Shirley CM, Chu SH, Li L, Nguyen BH, Seo J, Wu M, Seale T, Duffield AS, Staudt LM, Levis M, Hu Y, Small D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38811818"},{"title01":"Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u22651 prior tyrosine kinase inhibitor: 2-year follow-up results","title02":"Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u22651 prior tyrosine kinase inhibitor: 2-year follow-up results","journal":"Leukemia","issue":"2024 May 16. doi: 10.1038\/s41375-024-02278-8. Online ahead of print.","author":"Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38755421"},{"title01":"Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries","title02":"Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries","journal":"Leukemia","issue":"2024 May 18. doi: 10.1038\/s41375-024-02277-9. Online ahead of print.","author":"Rujkijyanont P, Inaba H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38762553"},{"title01":"AML\/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML","title02":"AML\/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML","journal":"Leukemia","issue":"2024 May 9. doi: 10.1038\/s41375-024-02255-1. Online ahead of print.","author":"Sayitoglu EC, Luca BA, Boss AP, Thomas BC, Freeborn RA, Uyeda MJ, Chen PP, Nakauchi Y, Waichler C, Lacayo N, Bacchetta R, Majeti R, Gentles AJ, Cepika AM, Roncarolo MG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38724673"},{"title01":"PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL","title02":"PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL","journal":"Leukemia","issue":"2024 May 9. doi: 10.1038\/s41375-024-02271-1. Online ahead of print.","author":"Farhat M, Croft W, Parry HM, Verma K, Kinsella FAM, Xu J, Bone D, McSkeane T, Paneesha S, Pratt G, Moss P, Zuo J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38724674"},{"title01":"Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia\/lymphoma: Experience from a tertiary care centre in South India","title02":"Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia\/lymphoma: Experience from a tertiary care centre in South India","journal":"Br J Haematol","issue":"2024 May 26. doi: 10.1111\/bjh.19559. Online ahead of print.","author":"Rupakumar T, Sankar A, Vijayasekharan K, Varikkattu Rajendran P, Chellapan Sojamani G, Rajeswari B, Nair M, Anandarajan R, Dennis D, Thankamony P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38797523"},{"title01":"RUNX1::ETO and CBF\u03b2::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia","title02":"RUNX1::ETO and CBF\u03b2::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia","journal":"Br J Haematol","issue":"2024 May 27. doi: 10.1111\/bjh.19565. Online ahead of print.","author":"Wang S, Liu Y, Zhao X, Wang X, Lou J, Jin P, Zhang Y, Yu J, Wang K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38802066"},{"title01":"Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1\/2 trial","title02":"Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1\/2 trial","journal":"Lancet Haematol","issue":"2024 Apr 30:S2352-3026(24)00078-4. doi: 10.1016\/S2352-3026(24)00078-4. Online ahead of print.","author":"Aygun B, Lane A, Smart LR, Santos B, Tshilolo L, Williams TN, Olupot-Olupot P, Stuber SE, Tomlinson G, Latham T, Ware RE; REACH Investigators.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38701812"},{"title01":"Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa","title02":"Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa","journal":"Lancet Haematol","issue":"2024 Apr 30:S2352-3026(24)00096-6. doi: 10.1016\/S2352-3026(24)00096-6. Online ahead of print.","author":"Galadanci NA, Kanter J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38701813"},{"title01":"Soluble urokinase plasminogen activator receptor is associated with kidney disease and its progression in sickle cell anemia","title02":"Soluble urokinase plasminogen activator receptor is associated with kidney disease and its progression in sickle cell anemia","journal":"Haematologica","issue":"2024 May 2. doi: 10.3324\/haematol.2023.284920. Online ahead of print.","author":"Zahr RS, Rashkin SR, Ruiz MA, Elsherif L, Ren G, Salas G, Ataga KI, Gordeuk VR, Lebensburger J, Zhang X, Saraf SL.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38695132"},{"title01":"Phase II trial of posaconazole prophylaxis during anti-thymocyte globulin treatment for aplastic anaemia and hypoplastic myelodysplastic syndrome","title02":"Phase II trial of posaconazole prophylaxis during anti-thymocyte globulin treatment for aplastic anaemia and hypoplastic myelodysplastic syndrome","journal":"Br J Haematol","issue":"2024 May 3. doi: 10.1111\/bjh.19500. Online ahead of print.","author":"Kim DH, Hong J, Shin DY, Kim I, Yoon SS, Bang SM, Lee JO, Lee JY, Kim SA, Byun JM, Koh Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38699798"},{"title01":"Mental health and use of psychotropic prescription drugs in adult patients with primary immune thrombocytopenia: a nationwide population-based cohort study","title02":"Mental health and use of psychotropic prescription drugs in adult patients with primary immune thrombocytopenia: a nationwide population-based cohort study","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2024.285364. Online ahead of print.","author":"Mannering N, Hansen DL, Potteg\u00e5rd A, Andersen K, Frederiksen H.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721747"},{"title01":"New findings and new methods on macrophages in primary immune thrombocytopenia","title02":"New findings and new methods on macrophages in primary immune thrombocytopenia","journal":"Br J Haematol","issue":"2024 May 3. doi: 10.1111\/bjh.19513. Online ahead of print.","author":"Ji L, Zhan Y, Cheng Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38699807"},{"title01":"Broadening the horizon of immune thrombocytopenia through Omics approaches","title02":"Broadening the horizon of immune thrombocytopenia through Omics approaches","journal":"Br J Haematol","issue":"2024 May 8. doi: 10.1111\/bjh.19514. Online ahead of print.","author":"Kapur R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38719342"},{"title01":"MN1::ETV6-positive de novo T-cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report","title02":"<i>MN1::ETV6<\/i>-positive de novo T-cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report","journal":"Br J Haematol","issue":"2024 Apr 29. doi: 10.1111\/bjh.19493. Online ahead of print.","author":"Zhang X, Zhong Y, Liu L, Suo S, Zhao S, Xiao F, Qin J, Tong H, Jin J, Yu W.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38685592"},{"title01":"The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network","title02":"The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-<i>a randomized, open-label phase III trial of the European mantle cell lymphoma network<\/i>","journal":"Leukemia","issue":"2024 Apr 27. doi: 10.1038\/s41375-024-02254-2. Online ahead of print.","author":"Fischer L, Jiang L, D\u00fcrig J, Schmidt C, Stilgenbauer S, Bouabdallah K, Solal-Celigny P, Scholz CW, Feugier P, de Wit M, Trappe RU, Hallek M, Graeven U, H\u00e4nel M, Hoffmann M, Delwail V, Macro M, Greiner J, Giagounidis AAN, Dargel B, Durot E, Foussard C, Silkenstedt E, Weigert O, Pott C, Klapper W, Hiddemann W, Unterhalt M, Hoster E, Ribrag V, Dreyling M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38678093"},{"title01":"Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?","title02":"Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?","journal":"Lancet Haematol","issue":"2024 Apr 24:S2352-3026(24)00097-8. doi: 10.1016\/S2352-3026(24)00097-8. Online ahead of print.","author":"Callander NS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38677301"},{"title01":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial","title02":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial","journal":"Lancet Haematol","issue":"2024 Apr 24:S2352-3026(24)00070-X. doi: 10.1016\/S2352-3026(24)00070-X. Online ahead of print.","author":"O'Donnell E, Mo C, Yee AJ, Nadeem O, Laubach J, Rosenblatt J, Munshi N, Midha S, Cirstea D, Chrysafi P, Horick N, Richardson PG, Raje N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38677302"},{"title01":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","title02":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","journal":"Lancet","issue":"2024 May 2:S0140-6736(24)00184-3. doi: 10.1016\/S0140-6736(24)00184-3. Online ahead of print.","author":"Dreyling M, Doorduijn J, Gin\u00e9 E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Lepp\u00e4 S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, H\u00e4nel M, Dierlamm J, Pott C, Klapper W, G\u00f6zel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38705160"},{"title01":"Does TRIANGLE take down transplantation in mantle cell lymphoma?","title02":"Does TRIANGLE take down transplantation in mantle cell lymphoma?","journal":"Lancet","issue":"2024 May 2:S0140-6736(24)00301-5. doi: 10.1016\/S0140-6736(24)00301-5. Online ahead of print.","author":"Martin P, Maddocks K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38705162"},{"title01":"Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival","title02":"Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival","journal":"J Clin Oncol","issue":"2024 May 3:JCO2300934. doi: 10.1200\/JCO.23.00934. Online ahead of print.","author":"Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Krishnan A, Landau H, Somlo G, Shah N, Stadtmauer E, Vogl DT, Vesole DH, McCarthy PL, Hahn T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38701390"},{"title01":"Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study","title02":"Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2023.284632. Online ahead of print.","author":"Oostenbrink LVE, Von Asmuth EGJ, Jol-van der Zijde CM, Jansen-Hoogendijk AM, Vervat C, Bredius RGM, Van Tol MJD, Schilham MW, Sedlacek P, Ifversen M, Balduzzi A, Bader P, Peters C, Moes DJAR, Lankester AC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721739"},{"title01":"Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors","title02":"Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2024.285002. Online ahead of print.","author":"Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos JD, Iida M, Karduss A, Purtill D, Elhaddad AM, Bazuaye NG, Bonfim C, De la Camara R, Chaudhri NA, Ciceri F, Correa C, Frutos C, Galeano S, Garderet L, Gonzalez-Ramella O, Greco R, Hamad N, Hazenberg MD, Horowitz MM, Kalwak K, Ko BS, Kodera Y, Koh MB, Liu K, McLornan DP, Moon JH, Neven B, Okamoto S, Pasquini MC, Passweg JR, Paulson K, Rondelli D, Ruggeri A, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Greinix H, Saber W, Aljurf M, Niederwieser D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721749"},{"title01":"Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis","title02":"Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis","journal":"Leukemia","issue":"2024 May 2. doi: 10.1038\/s41375-024-02256-0. Online ahead of print.","author":"Ramdial J, Kebriaei P, Champlin RE, Popat U, Rezvani K, Shpall EJ, Mehta RS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38698071"},{"title01":"Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders","title02":"Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders","journal":"Leukemia","issue":"2024 Apr 29. doi: 10.1038\/s41375-024-02258-y. Online ahead of print.","author":"Awada H, Gurnari C, Visconte V, Durmaz A, Kuzmanovic T, Awada H, Tu ZJ, Cook JR, Bolwell BJ, Sobecks R, Kalaycio M, Bosler D, Maciejewski JP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38684821"},{"title01":"Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?","title02":"Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?","journal":"Lancet Haematol","issue":"2024 Apr 24:S2352-3026(24)00097-8. doi: 10.1016\/S2352-3026(24)00097-8. Online ahead of print.","author":"Callander NS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38677301"},{"title01":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","title02":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","journal":"Lancet","issue":"2024 May 2:S0140-6736(24)00184-3. doi: 10.1016\/S0140-6736(24)00184-3. Online ahead of print.","author":"Dreyling M, Doorduijn J, Gin\u00e9 E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Lepp\u00e4 S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, H\u00e4nel M, Dierlamm J, Pott C, Klapper W, G\u00f6zel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38705160"},{"title01":"Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival","title02":"Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival","journal":"J Clin Oncol","issue":"2024 May 3:JCO2300934. doi: 10.1200\/JCO.23.00934. Online ahead of print.","author":"Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Krishnan A, Landau H, Somlo G, Shah N, Stadtmauer E, Vogl DT, Vesole DH, McCarthy PL, Hahn T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38701390"},{"title01":"Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study","title02":"Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2023.284632. Online ahead of print.","author":"Oostenbrink LVE, Von Asmuth EGJ, Jol-van der Zijde CM, Jansen-Hoogendijk AM, Vervat C, Bredius RGM, Van Tol MJD, Schilham MW, Sedlacek P, Ifversen M, Balduzzi A, Bader P, Peters C, Moes DJAR, Lankester AC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721739"},{"title01":"Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors","title02":"Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2024.285002. Online ahead of print.","author":"Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos JD, Iida M, Karduss A, Purtill D, Elhaddad AM, Bazuaye NG, Bonfim C, De la Camara R, Chaudhri NA, Ciceri F, Correa C, Frutos C, Galeano S, Garderet L, Gonzalez-Ramella O, Greco R, Hamad N, Hazenberg MD, Horowitz MM, Kalwak K, Ko BS, Kodera Y, Koh MB, Liu K, McLornan DP, Moon JH, Neven B, Okamoto S, Pasquini MC, Passweg JR, Paulson K, Rondelli D, Ruggeri A, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Greinix H, Saber W, Aljurf M, Niederwieser D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721749"},{"title01":"Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation","title02":"Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation","journal":"Blood","issue":"2024 Apr 26:blood.2023022697. doi: 10.1182\/blood.2023022697. Online ahead of print.","author":"Wienecke CP, Heida B, Venturini L, Gabdoulline R, Kr\u00fcger K, Teich K, B\u00fcttner K, Wichmann M, Puppe W, Neziri B, Reuter M, Dammann E, Stadler M, Ganser A, Hambach L, Thol FR, Heuser M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38669617"},{"title01":"Outcomes of HLA-mismatched HSCT with TCR\u03b1\u03b2\/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity","title02":"Outcomes of HLA-mismatched HSCT with TCR\u03b1\u03b2\/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity","journal":"Blood","issue":"2024 Apr 26:blood.2024024038. doi: 10.1182\/blood.2024024038. Online ahead of print.","author":"Lum SH, Albert MH, Gilbert P, Sirait T, Algeri M, Muratori R, Fournier B, Laberko A, Karakukcu M, Unal E, Ayas MF, Yadav SP, Fisgin T, Elfeky R, Fernandes JF, Faraci M, Cole T, Schulz AS, Meisel R, Zecca M, Ifversen M, Biffi A, Diana JS, Vall\u00e9e TC, Giardino S, Ersoy GZ, Moshous D, Gennery AR, Balashov D, Bonfim CMS, Locatelli F, Lankester AC, Neven B, Slatter MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38669631"},{"title01":"HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","title02":"HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","journal":"Blood","issue":"2024 Apr 29:blood.2024024105. doi: 10.1182\/blood.2024024105. Online ahead of print.","author":"Krakow EF, Brault M, Summers C, Cunningham TM, Biernacki MA, Black RG, Woodward KB, Vartanian N, Kanaan SB, Yeh AC, Dossa RG, Bar M, Cassaday RD, Dahlberg A, Till BG, Denker AE, Yeung CCS, Gooley TA, Maloney DG, Riddell SR, Greenberg PD, Chapuis AG, Newell EW, Furlan SN, Bleakley M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38683966"},{"title01":"Kinase-inactivated CDK6 preserves the long-term functionality of adult hematopoietic stem cells","title02":"Kinase-inactivated CDK6 preserves the long-term functionality of adult hematopoietic stem cells","journal":"Blood","issue":"2024 Apr 29:blood.2023021985. doi: 10.1182\/blood.2023021985. Online ahead of print.","author":"Mayer IM, Doma E, Klampfl T, Prchal-Murphy M, Kollmann S, Schirripa A, Scheiblecker L, Zojer M, Kunowska N, Gebrail L, Shaw LE, Mann U, Farr A, Grausenburger R, Heller G, Zebedin-Brandl E, Farlik M, Malumbres M, Sexl V, Kollmann K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38684032"},{"title01":"Impact of Hematopoietic Cell Transplantation on Myocardial Fibrosis in Young Patients with Sickle Cell Disease","title02":"Impact of Hematopoietic Cell Transplantation on Myocardial Fibrosis in Young Patients with Sickle Cell Disease","journal":"Blood","issue":"2024 May 1:blood.2023023028. doi: 10.1182\/blood.2023023028. Online ahead of print.","author":"Sharma A, Selukar S, Bi Y, Merlocco A, Morin C, Goode C, Rai P, Towbin JA, Hankins JS, Gottschalk S, Triplett BM, Johnson JN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38691679"},{"title01":"Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement","title02":"Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement","journal":"Lancet Haematol","issue":"2024 May;11(5):e368-e382.","author":"Wlodarski MW, Vlachos A, Farrar JE, Da Costa LM, Kattamis A, Dianzani I, Belendez C, Unal S, Tamary H, Pasauliene R, Pospisilova D, de la Fuente J, Iskander D, Wolfe L, Liu JM, Shimamura A, Albrecht K, Lausen B, Bechensteen AG, Tedgard U, Puzik A, Quarello P, Ramenghi U, Bartels M, Hengartner H, Farah RA, Al Saleh M, Hamidieh AA, Yang W, Ito E, Kook H, Ovsyannikova G, Kager L, Gleizes PE, Dalle JH, Strahm B, Niemeyer CM, Lipton JM, Leblanc TM; international Diamond-Blackfan anaemia syndrome guideline panel.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38697731"},{"title01":"From niche to blockbuster: a greater role for allopurinol in maintenance treatment of acute lymphoblastic leukemia","title02":"From niche to blockbuster: a greater role for allopurinol in maintenance treatment of acute lymphoblastic leukemia","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2024.285080. Online ahead of print.","author":"Stanulla M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721742"},{"title01":"Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN","title02":"Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN","journal":"Haematologica","issue":"2024 May 2. doi: 10.3324\/haematol.2023.283428. Online ahead of print.","author":"Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Saglio G.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38695123"},{"title01":"The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort","title02":"The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort","journal":"Haematologica","issue":"2024 May 2. doi: 10.3324\/haematol.2023.284860. Online ahead of print.","author":"Saugues S, Lambert C, Daguenet E, Roth-Guepin G, Huguet F, Cony-Makhoul P, Ansah HJ, Escoffre-Barbe M, Turhan A, Rousselot P, Tchirkov A, Hamroun D, Hermet E, Pereira B, Berger MG.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38695126"},{"title01":"CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia","title02":"CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia","journal":"Haematologica","issue":"2024 May 2. doi: 10.3324\/haematol.2023.284241. Online ahead of print.","author":"Jin X, Sun R, Li Z, Wang X, Xiong X, Lu W, Lyu H, Xiao X, Tian Y, Zhang H, Fang Z, Wang L, Zhao M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38695137"},{"title01":"Minimal residual disease monitoring in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia: prognostic significance and correlation between multiparameter flow cytometry and real-time quantitative polymerase chain reaction","title02":"Minimal residual disease monitoring in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia: prognostic significance and correlation between multiparameter flow cytometry and real-time quantitative polymerase chain reaction","journal":"Haematologica","issue":"2024 May 2. doi: 10.3324\/haematol.2024.285119. Online ahead of print.","author":"Li J, Lu A, Gao Y, Wan Y, Wang J, Zhang J, Hu T, Wu P, Chen X, Zou Y, Chen Y, Zhang L, Guo Y, Yang W, Li C, Zhang Y, Zhu X.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38695139"},{"title01":"Outcomes and genetic dynamics of acute myeloid leukemia at first relapse","title02":"Outcomes and genetic dynamics of acute myeloid leukemia at first relapse","journal":"Haematologica","issue":"2024 May 2. doi: 10.3324\/haematol.2024.285057. Online ahead of print.","author":"Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38695144"},{"title01":"Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy","title02":"Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy","journal":"Br J Haematol","issue":"2024 May 2. doi: 10.1111\/bjh.19491. Online ahead of print.","author":"Robertson HF, Milojkovic D, Butt N, Byrne J, Claudiani S, Copland M, Gallipoli P, Innes AJ, Knight K, Mahdi AJ, Parker J, Virchis A, Apperley JF.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38698705"},{"title01":"Clinical characteristics of acute myeloid leukaemia patients with a large number of azurophilic granules: A single-centre retrospective study","title02":"Clinical characteristics of acute myeloid leukaemia patients with a large number of azurophilic granules: A single-centre retrospective study","journal":"Br J Haematol","issue":"2024 May 6. doi: 10.1111\/bjh.19494. Online ahead of print.","author":"Zhao S, Wang J, Lou Y, Huang X, Xie W, Yu W, Liu L, Zhu Y, Gao X, Ma G, Zhou Z, Ghoushi E, Ghafouri M, Jin J, Tong H, Zhou D.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38706448"},{"title01":"Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens","title02":"Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens","journal":"Br J Haematol","issue":"2024 May 6. doi: 10.1111\/bjh.19517. Online ahead of print.","author":"Serafin A, Cellini A, Cavarretta CA, Ruocco V, Angotzi F, Zatta I, Frezzato F, Bonaldi L, Martines A, Pravato S, Piazza F, Trentin L, Visentin A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38710589"},{"title01":"The Menin story in acute myeloid leukaemia-The road to success","title02":"The Menin story in acute myeloid leukaemia-The road to success","journal":"Br J Haematol","issue":"2024 May 6. doi: 10.1111\/bjh.19508. Online ahead of print.","author":"K\u00fchn MWM, Ganser A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38710595"},{"title01":"Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia","title02":"Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia","journal":"Br J Haematol","issue":"2024 Apr 29. doi: 10.1111\/bjh.19492. Online ahead of print.","author":"Xu J, Peng J, Sun S, Wang D, Yuan W, Yang X, Shi T, Wang R, Liu H, Zhang P, Zhu HH.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38685813"},{"title01":"Decitabine in Older Patients with AML: Quality of Life Results of the EORTC-GIMEMA-GMDS-SG Randomized Phase III Trial","title02":"Decitabine in Older Patients with AML: Quality of Life Results of the EORTC-GIMEMA-GMDS-SG Randomized Phase III Trial","journal":"Blood","issue":"2024 May 8:blood.2023023625. doi: 10.1182\/blood.2023023625. Online ahead of print.","author":"Efficace F, Kicinski M, Coens C, Suciu S, van der Velden WJFM, Noppeney R, Chantepie SP, Griskevicius L, Neubauer A, Audisio E, Luppi M, Fuhrmann S, Fo\u00e0 R, Crysandt M, Gaidano G, Vrhovac R, Venditti A, Posthuma EFM, Candoni A, Baron F, Legrand O, Mengarelli A, Fazi P, Vignetti M, Giraut A, Wijermans PW, Huls GA, L\u00fcbbert M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38717861"},{"title01":"Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation","title02":"Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation","journal":"Blood","issue":"2024 Apr 26:blood.2023022697. doi: 10.1182\/blood.2023022697. Online ahead of print.","author":"Wienecke CP, Heida B, Venturini L, Gabdoulline R, Kr\u00fcger K, Teich K, B\u00fcttner K, Wichmann M, Puppe W, Neziri B, Reuter M, Dammann E, Stadler M, Ganser A, Hambach L, Thol FR, Heuser M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38669617"},{"title01":"HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","title02":"HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","journal":"Blood","issue":"2024 Apr 29:blood.2024024105. doi: 10.1182\/blood.2024024105. Online ahead of print.","author":"Krakow EF, Brault M, Summers C, Cunningham TM, Biernacki MA, Black RG, Woodward KB, Vartanian N, Kanaan SB, Yeh AC, Dossa RG, Bar M, Cassaday RD, Dahlberg A, Till BG, Denker AE, Yeung CCS, Gooley TA, Maloney DG, Riddell SR, Greenberg PD, Chapuis AG, Newell EW, Furlan SN, Bleakley M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38683966"},{"title01":"T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia","title02":"T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia","journal":"Blood","issue":"2024 Apr 29:blood.2023021990. doi: 10.1182\/blood.2023021990. Online ahead of print.","author":"Roessner PM, Seufert I, Chapaprieta V, Jayabalan R, Briesch H, Massoni-Badosa R, Boskovic P, Beckendorff J, Roider T, Arseni L, Coelho M, Chakraborty S, Vaca A, Sivina M, Muckenhuber M, Rodriguez-Rodriguez S, Bonato A, Herbst SA, Zapatka M, Sun C, Kretzmer H, Naake T, Bruch PM, Czernilofsky F, Ten Hacken E, Schneider M, Helm D, Yosifov DY, Kauer J, Danilov AV, Bewarder M, Heyne K, Schneider C, Stilgenbauer S, Wiestner A, Mallm JP, Burger JA, Efremov DG, Lichter P, Dietrich S, Mart\u00edn-Subero JI, Rippe K, Seiffert M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38684038"},{"title01":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","title02":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","journal":"Lancet","issue":"2024 May 2:S0140-6736(24)00184-3. doi: 10.1016\/S0140-6736(24)00184-3. Online ahead of print.","author":"Dreyling M, Doorduijn J, Gin\u00e9 E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Lepp\u00e4 S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, H\u00e4nel M, Dierlamm J, Pott C, Klapper W, G\u00f6zel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38705160"},{"title01":"Does TRIANGLE take down transplantation in mantle cell lymphoma?","title02":"Does TRIANGLE take down transplantation in mantle cell lymphoma?","journal":"Lancet","issue":"2024 May 2:S0140-6736(24)00301-5. doi: 10.1016\/S0140-6736(24)00301-5. Online ahead of print.","author":"Martin P, Maddocks K.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38705162"},{"title01":"Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy","title02":"Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2023.284197. Online ahead of print.","author":"Tarantelli C, Wald D, Munz N, Spriano F, Bruscaggin A, Cannas E, Cascione L, Gaudio E, Arribas AJ, Manjappa S, Golino G, Scalise L, Cacciapuoti MT, Zucca E, Stathis A, Inghirami G, Van Berkel PH, Rossi D, Caimi PF, Zammarchi F, Bertoni F.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721745"},{"title01":"A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report","title02":"A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2023.284881. Online ahead of print.","author":"Elice F, Sommaggio R, Cappuzzello E, Riva M, Tisi MC, Bernardi M, Bozza A, Catanzaro D, Chieregato K, Merlo A, Giaretta I, Pieta AD, Krampera M, Visco C, Trentin L, Visentin A, Tosetto A, Astori G, Rosato A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721751"},{"title01":"Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed\/refractory primary mediastinal large B-cell lymphoma","title02":"Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed\/refractory primary mediastinal large B-cell lymphoma","journal":"Haematologica","issue":"2024 May 2. doi: 10.3324\/haematol.2023.284689. Online ahead of print.","author":"Renaud L, Wencel J, Pag\u00e8s A, Al Jijakli A, Moatti H, Quero L, Camus V, Brice P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38695142"},{"title01":"Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma","title02":"Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma","journal":"Br J Haematol","issue":"2024 May 2. doi: 10.1111\/bjh.19478. Online ahead of print.","author":"Kuczmarski TM, Lynch RC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38698683"},{"title01":"Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study","title02":"Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study","journal":"Br J Haematol","issue":"2024 Apr 29. doi: 10.1111\/bjh.19475. Online ahead of print.","author":"Vandtved JH, \u00d8vlisen AK, Baech J, Weinrich UM, Severinsen MT, Maksten EF, Jakobsen LH, Glimelius I, Kamper P, Hutchings M, Specht L, Dahl-S\u00f8rensen R, Christensen JH, El-Galaly TC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38685596"},{"title01":"Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis","title02":"Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis","journal":"Blood","issue":"2024 May 2:blood.2023023419. doi: 10.1182\/blood.2023023419. Online ahead of print.","author":"Kim J, Cho J, Lee MH, Yoon SE, Kim WS, Kim SJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38696731"},{"title01":"Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study","title02":"Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study","journal":"Blood","issue":"2024 May 3:blood.2024024251. doi: 10.1182\/blood.2024024251. Online ahead of print.","author":"Hilton LK, Collinge BJ, Ben-Neriah S, Alduaij W, Shaalan H, Weng A, Cruz M, Slack GW, Farinha P, Miyata-Takata T, Boyle M, Meissner B, Cook JR, Ondrejka SL, Ott G, Rosenwald A, Campo E, Amador C, Greiner TC, Raess PW, Song JY, Inghirami GG, Jaffe ES, Weisenburger DD, Chan WC, Beiske K, Fu K, Delabie J, Pittaluga S, Iqbal J, Wright G, Sehn LH, Savage KJ, Mungall AJ, Feldman AL, Staudt LM, Steidl C, Rimsza LM, Morin RD, Scott DW.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38701426"},{"title01":"Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients","title02":"Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients","journal":"Blood","issue":"2024 Apr 26:blood.2024023944. doi: 10.1182\/blood.2024023944. Online ahead of print.","author":"Sarkozy C, Callanan MB, Thieblemont C, Ob\u00e9ric L, Burroni B, Bouabdallah K, Damaj G, Tessoulin B, Ribrag V, Houot R, Morschhauser F, Griolet S, Joubert C, Cacheux V, Delwail V, Safar V, Gressin R, Cheminant M, Delfau-Larue MH, Hermine O, Macintyre EA, Le Gouill S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38669626"},{"title01":"Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach","title02":"Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach","journal":"Leukemia","issue":"2024 Apr 30. doi: 10.1038\/s41375-024-02247-1. Online ahead of print.","author":"Walker IG, Roy JP, Anderson GSF, Guerrero Lopez J, Chapman MA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38688994"},{"title01":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","title02":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","journal":"Lancet Oncol","issue":"2024 May;25(5):e205-e216.","author":"Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, P\u00e9rez-Larraya JG, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, H\u00e1jek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL; International Myeloma Working Group.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38697166"},{"title01":"Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?","title02":"Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?","journal":"Lancet Haematol","issue":"2024 Apr 24:S2352-3026(24)00097-8. doi: 10.1016\/S2352-3026(24)00097-8. Online ahead of print.","author":"Callander NS.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38677301"},{"title01":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial","title02":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial","journal":"Lancet Haematol","issue":"2024 Apr 24:S2352-3026(24)00070-X. doi: 10.1016\/S2352-3026(24)00070-X. Online ahead of print.","author":"O'Donnell E, Mo C, Yee AJ, Nadeem O, Laubach J, Rosenblatt J, Munshi N, Midha S, Cirstea D, Chrysafi P, Horick N, Richardson PG, Raje N.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38677302"},{"title01":"Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival","title02":"Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival","journal":"J Clin Oncol","issue":"2024 May 3:JCO2300934. doi: 10.1200\/JCO.23.00934. Online ahead of print.","author":"Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Krishnan A, Landau H, Somlo G, Shah N, Stadtmauer E, Vogl DT, Vesole DH, McCarthy PL, Hahn T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38701390"},{"title01":"Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed\/refractory multiple myeloma: Results from a prospective comprehensive biomarker study","title02":"Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed\/refractory multiple myeloma: Results from a prospective comprehensive biomarker study","journal":"Br J Haematol","issue":"2024 May 8. doi: 10.1111\/bjh.19515. Online ahead of print.","author":"Zhou X, Wagner V, Scheller L, Stanojkovska E, Riedhammer C, Xiao X, Steinhardt MJ, Vogt C, Nerreter S, Eisele F, John M, Munawar U, Kadel SK, Mersi J, Ruckdeschel A, Schimanski S, Haertle L, Waldschmidt JM, Han S, Topp M, Duell J, Einsele H, Riedel A, Kort\u00fcm KM, Rasche L.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38719214"},{"title01":"The role of proliferating stem-like plasma cells in relapsed or refractory multiple myeloma: Insights from single-cell RNA sequencing and proteomic analysis","title02":"The role of proliferating stem-like plasma cells in relapsed or refractory multiple myeloma: Insights from single-cell RNA sequencing and proteomic analysis","journal":"Br J Haematol","issue":"2024 Apr 26. doi: 10.1111\/bjh.19486. Online ahead of print.","author":"Xu J, Li P, Wang Y, Li J, Xu B, Zhao J, Chen C, Gu S, Ding C, Liu P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38671576"},{"title01":"Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide","title02":"Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide","journal":"Br J Haematol","issue":"2024 Apr 29. doi: 10.1111\/bjh.19468. Online ahead of print.","author":"Lin Z, Zhang Y, Liu X, Luo H, Li Q, Gao Q, Wang X, Wen J, Li L, Feng Y, Wang F, Huang J, Zhai X, Zhang L, Niu T, Zheng Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38685577"},{"title01":"Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma","title02":"Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma","journal":"Blood","issue":"2024 May 7:blood.2024024041. doi: 10.1182\/blood.2024024041. Online ahead of print.","author":"Kubicki T, Dytfeld D, Barnidge DR, Sakrikar D, Przyby\u0142owicz-Chalecka A, Jamroziak K, Robak P, Czyz J, Tyczynska A, Druzd-Sitek AA, Giannopoulos K, Wr\u00f3bel T, Nowicki A, Szczepaniak T, \u0141ojko-Dankowska A, Matuszak M, Gil LA, Pu\u0142a B, Szukalski L, Ko\u0144ska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T Prof, Jiang K, Cooperrider JH, Jakubowiak AJ, Derman BA.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38713888"},{"title01":"Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders","title02":"Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders","journal":"Leukemia","issue":"2024 Apr 29. doi: 10.1038\/s41375-024-02258-y. Online ahead of print.","author":"Awada H, Gurnari C, Visconte V, Durmaz A, Kuzmanovic T, Awada H, Tu ZJ, Cook JR, Bolwell BJ, Sobecks R, Kalaycio M, Bosler D, Maciejewski JP.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38684821"},{"title01":"InsT-ALLing CD7 chimeric antigen receptors before transplantation","title02":"InsT-ALLing CD7 chimeric antigen receptors before transplantation","journal":"Br J Haematol","issue":"2024 Apr 26. doi: 10.1111\/bjh.19498. Online ahead of print.","author":"Delgado J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38676290"},{"title01":"Donor-derived CD8-predominant T cells in human graft-versus-host disease of the brain after allogeneic transplantation","title02":"Donor-derived CD8-predominant T cells in human graft-versus-host disease of the brain after allogeneic transplantation","journal":"Br J Haematol","issue":"2024 May 1. doi: 10.1111\/bjh.19504. Online ahead of print.","author":"Nishikubo M, Matsuo H, Manabe S, Ota K, Ishii J, Hiramoto N, Hara S, Kondo T, Ishikawa T.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38693664"},{"title01":"Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation","title02":"Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation","journal":"Blood","issue":"2024 Apr 26:blood.2023022697. doi: 10.1182\/blood.2023022697. Online ahead of print.","author":"Wienecke CP, Heida B, Venturini L, Gabdoulline R, Kr\u00fcger K, Teich K, B\u00fcttner K, Wichmann M, Puppe W, Neziri B, Reuter M, Dammann E, Stadler M, Ganser A, Hambach L, Thol FR, Heuser M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38669617"},{"title01":"Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients","title02":"Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients","journal":"Blood","issue":"2024 Apr 26:blood.2024023944. doi: 10.1182\/blood.2024023944. Online ahead of print.","author":"Sarkozy C, Callanan MB, Thieblemont C, Ob\u00e9ric L, Burroni B, Bouabdallah K, Damaj G, Tessoulin B, Ribrag V, Houot R, Morschhauser F, Griolet S, Joubert C, Cacheux V, Delwail V, Safar V, Gressin R, Cheminant M, Delfau-Larue MH, Hermine O, Macintyre EA, Le Gouill S.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38669626"},{"title01":"HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","title02":"HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","journal":"Blood","issue":"2024 Apr 29:blood.2024024105. doi: 10.1182\/blood.2024024105. Online ahead of print.","author":"Krakow EF, Brault M, Summers C, Cunningham TM, Biernacki MA, Black RG, Woodward KB, Vartanian N, Kanaan SB, Yeh AC, Dossa RG, Bar M, Cassaday RD, Dahlberg A, Till BG, Denker AE, Yeung CCS, Gooley TA, Maloney DG, Riddell SR, Greenberg PD, Chapuis AG, Newell EW, Furlan SN, Bleakley M.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38683966"},{"title01":"Impact of Hematopoietic Cell Transplantation on Myocardial Fibrosis in Young Patients with Sickle Cell Disease","title02":"Impact of Hematopoietic Cell Transplantation on Myocardial Fibrosis in Young Patients with Sickle Cell Disease","journal":"Blood","issue":"2024 May 1:blood.2023023028. doi: 10.1182\/blood.2023023028. Online ahead of print.","author":"Sharma A, Selukar S, Bi Y, Merlocco A, Morin C, Goode C, Rai P, Towbin JA, Hankins JS, Gottschalk S, Triplett BM, Johnson JN.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38691679"},{"title01":"Acute Promyelocytic Leukemia","title02":"Acute Promyelocytic Leukemia","journal":"N Engl J Med","issue":"2024 May 2;390(17):e42.","author":"Winkler C.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38683728"},{"title01":"Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease","title02":"Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease","journal":"N Engl J Med","issue":"2024 May 2;390(17):1633-1634.","author":"Wang WD, Gale RP, Liang Y.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38692303"},{"title01":"Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. Reply","title02":"Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. Reply","journal":"N Engl J Med","issue":"2024 May 2;390(17):1634-1635.","author":"Munir T, Hillmen P.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38692304"},{"title01":"When leukaemia masquerades: the hidden syphilis diagnosis","title02":"When leukaemia masquerades: the hidden syphilis diagnosis","journal":"Lancet Oncol","issue":"2024 May;25(5):e225.","author":"Musicante M, Harrell JM, Kubicki S, Curry JL, Patel AB.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38697168"},{"title01":"A case of familial donor-derived acute myeloid leukemia with underlying pre-leukemic mutations","title02":"A case of familial donor-derived acute myeloid leukemia with underlying pre-leukemic mutations","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2024.285156. Online ahead of print.","author":"Cappelli LV, Minotti C, Meggendorfer M, Truger M, Haferlach T, Mecucci C, Matteucci C, Alati C, Iori AP, Martelli M, Fo\u00e0 R.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721723"},{"title01":"The diversity of the microbiome impacts chronic lymphocytic leukemia development in mice and humans","title02":"The diversity of the microbiome impacts chronic lymphocytic leukemia development in mice and humans","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2023.284693. Online ahead of print.","author":"Faitova T, Coelho M, Da Cunha-Bang C, Ozturk S, Kartal E, Bork P, Seiffert M, Niemann CU.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721725"},{"title01":"Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 Protocol","title02":"Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 Protocol","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2024.285285. Online ahead of print.","author":"Zeller B, Arad-Cohen N, Cheuk D, De Moerloose B, Navarro JMF, Hasle H, Jahnukainen K, Juul-Dam KL, Kaspers G, Kovalova Z, Jonsson OG, Lausen B, Munthe-Kaas M, Nystrom UN, Palle J, Pasauliene R, Pronk CJ, Saks K, Tierens A, Abrahamsson J.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721737"},{"title01":"Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study","title02":"Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2023.284632. Online ahead of print.","author":"Oostenbrink LVE, Von Asmuth EGJ, Jol-van der Zijde CM, Jansen-Hoogendijk AM, Vervat C, Bredius RGM, Van Tol MJD, Schilham MW, Sedlacek P, Ifversen M, Balduzzi A, Bader P, Peters C, Moes DJAR, Lankester AC.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721739"},{"title01":"Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML","title02":"Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML","journal":"Blood","issue":"2024 May 1:blood.2024024310. doi: 10.1182\/blood.2024024310. Online ahead of print.","author":"Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, Freeman SD, Gilkes AF, Gale RE, Rapoz-D'Silva T, Runglall M, Kleeman M, Dhami P, Thomas I, Johnson S, Canham J, Cavenagh JD, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett AK -, Wilhelm-Benartzi CS, Huntly BJ, Russell NH, Dillon RJ.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38691678"},{"title01":"Cachexia during anti-leukemia chemotherapy: it is not &#8220;just&#8221; the chemo","title02":"Cachexia during anti-leukemia chemotherapy: it is not &#8220;just&#8221; the chemo","journal":"Haematologica","issue":"2024 May 9. doi: 10.3324\/haematol.2024.285455. Online ahead of print.","author":"Rashidi A.","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/38721740"}]